Lupus develops when genetically predisposed people encounter environmental agents that initiate flares. Current evidence indicates that the environmental contribution is mediated by T-cell DNA demethylation. DNA methylation patterns are established during differentiation, and silence inappropriate or unnecessary genes by promoting a condensed chromatin configuration that is inaccessible to transcription factors. The methylation patterns are then replicated each time a cell divides by DNA methyltransferase 1 (Dnmt1). Dnmt1 is upregulated during mitosis, binds the replication fork, and catalyzes transfer of the methyl group from S-adenosylmethionine (SAM) to dC bases in the daughter DNA strand only where the parent strand is methylated. Environmental agents that block ERK pathway signaling prevent Dnmt1 upregulation, and low Dnmt1 levels synergize with dietary micronutrient deficiencies that decrease SAM pools to impair methylation of the daughter strand. This activates genes silenced only by DNA methylation. Inhibiting T-cell DNA methylation converts helper CD4 + T cells into autoreactive, cytotoxic, proinflammatory cells that cause lupus-like autoimmunity in mice. Similar changes in CD4 + T-cell DNA methylation and gene expression are found in patients with active lupus. Procainamide and hydralazine, which cause ANAs in a majority of patients and lupus in a genetically predisposed subset, also inhibit T-cell DNA methylation. The lupus T-cell DNA methylation defect has been traced to low Dnmt1 levels caused by decreased ERK pathway signaling, and the signaling defect has now been traced to PKCδ inactivation caused by oxidative damage. The importance of decreased ERK pathway signaling was confirmed by generating a transgenic mouse with an inducible dominant negative MEK. Inducing the signaling defect selectively in T cells decreases Dnmt1, causing anti-DNA antibodies in mice without lupus genes, and higher anti-DNA antibody levels and an immune complex glomerulonephritis in mice with lupus genes. Autoantibody levels and kidney disease are suppressed by dietary transmethylation micronutrient supplementation in these mice. Epigenetic mechanisms also contribute to the gender dimorphism in lupus.
Lupus develops when genetically predisposed people encounter environmental agents that initiate flares. Current evidence indicates that the environmental contribution is mediated by T-cell DNA demethylation. DNA methylation patterns are established during differentiation, and silence inappropriate or unnecessary genes by promoting a condensed chromatin configuration that is inaccessible to transcription factors. The methylation patterns are then replicated each time a cell divides by DNA methyltransferase 1 (Dnmt1). Dnmt1 is upregulated during mitosis, binds the replication fork, and catalyzes transfer of the methyl group from S-adenosylmethionine (SAM) to dC bases in the daughter DNA strand only where the parent strand is methylated. Environmental agents that block ERK pathway signaling prevent Dnmt1 upregulation, and low Dnmt1 levels synergize with dietary micronutrient deficiencies that decrease SAM pools to impair methylation of the daughter strand. This activates genes silenced only by DNA methylation. Inhibiting T-cell DNA methylation converts helper CD4 + T cells into autoreactive, cytotoxic, proinflammatory cells that cause lupus-like autoimmunity in mice. Similar changes in CD4 + T-cell DNA methylation and gene expression are found in patients with active lupus. Procainamide and hydralazine, which cause ANAs in a majority of patients and lupus in a genetically predisposed subset, also inhibit T-cell DNA methylation. The lupus T-cell DNA methylation defect has been traced to low Dnmt1 levels caused by decreased ERK pathway signaling, and the signaling defect has now been traced to PKCδ inactivation caused by oxidative damage. The importance of decreased ERK pathway signaling was confirmed by generating a transgenic mouse with an inducible dominant negative MEK. Inducing the signaling defect selectively in T cells decreases Dnmt1, causing anti-DNA antibodies in mice without lupus genes, and higher anti-DNA antibody levels and an immune complex glomerulonephritis in mice with lupus genes. Autoantibody levels and kidney disease are suppressed by dietary transmethylation micronutrient supplementation in these mice. Epigenetic mechanisms also contribute to the gender dimorphism in lupus.
Immune genes on the normally silenced X chromosome demethylate in women with active lupus, contributing to flare severity. In contrast, men with only one X chromosome require a greater genetic predisposition and/ or greater degree of DNA demethylation to develop a lupus flare equal in severity to women. Together, these studies indicate that environmental agents including oxidative stress and diet combine to inhibit T-cell DNA methylation, and that the epigenetically modified cells cause lupus-like autoimmunity in genetically predisposed people and mice. Background: CD4 T cells help B cells produce antibodies following antigen challenge. This response classically occurs in germinal centers (GC) located in B-cell follicles of secondary lymphoid organs (SLO), a site of immunoglobulin isotype switching and affinity maturation. GC formation requires specialized CD4 T cells, T-follicular helper (Tfh) cells, which localize to follicles and provide B cells with survival and differentiation signals that are essential for B-cell maturation into memory and long-lived plasma cells. Pathogenic autoantibodies in human and murine lupus arise in a like manner. Although Tfh cells are critical for GC development, their genesis in humans, role in promotion of autoimmunity, and potential as therapeutic targets in SLE are incompletely understood. To address these issues, we dissected Tfh cell development and function, defining their transcriptional regulation, migration, and function in vivo in normal and lupus-prone mice and ex vivo in normal humans and patients with SLE. Methods: We used a combination of approaches -flow cytometry, confocal microscopy, microarrays, quantitative chromatin immunoprecipitation and DNA sequencing (ChIP-seq), retroviral overexpression, and T-cell-B-cell helper assays -to characterize Tfh cells in normal mice and in lupus-prone strains, and from the tonsils of normal humans and the blood of patients with SLE. Results: We found that the transcription factor Bcl6 (B-cell CLL/lymphoma 6) is necessary and sufficient for Tfh development and function, via genetic control of Tfh proteins that are essential for their migration to B-cell follicles and GC and subsequent B-cell maturation. We dissected steps in Tfh development within SLO, beginning with their genesis in the T-cell zone followed by emigration to sites of B-cell interaction outside the B-cell follicle, where we have shown that B cells serve to provide signals for continued Tfh expansion and follicular migration. We have now begun to tease apart the factors that mediate T-cell-B-cell collaboration in the follicle; these represent therapeutic targets in SLE. Finally, we have shown that patients with SLE have expansion of Tfh cells in the blood, a finding that highlights their potential role in the pathogenesis of SLE and as likely therapeutic targets. Conclusion: These studies help define the developmental pathways for Tfh cells, and the steps that enable these cells to function in the B-cell follicle to promote immunoglobulin and autoantibody production. They have also helped define markers of Tfh cells in normals and autoimmune individuals, and suggest that they are a promising therapeutic target in patients.
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Longitudinal analysis of mRNA transcripts and plasma proteins to define a biomarker associated with lupus disease activity M Olferiev 1 Objective: Lupus, a chronic autoimmune disease, is characterized by a variable clinical course, with periods of active disease. Identification of a biomarker or biomarker panel associated with clinical disease activity would be useful for disease management, assessment of response to therapeutic intervention in practice or clinical trials, and might suggest cellular or molecular targets for future therapies. To identify biomarkers that reflect lupus disease activity, we assessed longitudinal clinical, gene expression and proteomic data from SLE patients. Methods: One hundred and sixty-nine RNA extracts from PBMC and plasma samples were collected longitudinally (up to 3 years) from 23 SLE patients and five healthy donors (HD), and SLEDAI and BILAG scores were recorded. All SLE patients fulfilled ACR criteria for the disease. PBMC mRNA profiles for each visit were established using Affymetrix GeneChips. A panel of proinflammatory cytokines was evaluated using Multi-Analyte Profiling technology (Rules-Based Medicine, Austin, TX, USA). Longitudinal data analysis was performed using R (R Development Core Team) and the R packages lme4 and languageR. Data were analyzed using linear mixedeffects (LME) models. Results: K-mean cluster analysis was first used to identify groups of gene transcripts that fluctuate in relation to disease activity, and representative transcripts were selected from each cluster. Thirteen plasma factors were identified as significantly increased in SLE patients compared with HD, and 14 plasma factors were significantly associated with disease activity. LME analysis was applied to the dataset to identify those transcripts and plasma factors that best define clinical disease activity. Statistical correlation with disease activity for this biomarker panel was compared with traditional measures of disease activity. Conclusion: A combination of mRNA transcripts and plasma factors, when assessed as a panel, shows a high correlation with clinical disease activity in patients with SLE. Validation of this biomarker panel in an extended patient group may provide support for measurement of these transcripts and proteins as an informative correlate of disease activity and a tool for patient management. The past decade has brought unprecedented progress in the refinement of conventional therapies for systemic lupus erythematosus (SLE) and the development of biologic therapies for SLE. Extensive recent evidence has expanded our understanding of the potential benefits of antimalarial therapy and has demonstrated improved approaches to the use of cyclophosphamide. Concurrently, a strong foundation of evidence has been generated to support the use of mycophenolate mofetil, especially in lupus nephritis. Against this background, there has been mounting excitement surrounding the promise of biologic therapies. Belimumab demonstrated efficacy in two phase III trials involving patients with diverse, nonrenal non-CNS, manifestations of SLE. The success of these trials has drawn attention to a novel primary endpoint, the SLE Responder Index (SRI). In this regard, it bears emphasizing that the trials were positive because the drug had a demonstrable effect, not because of the novelty of the endpoint. Indeed, the SLEDAI component of the outcome measure distinguished the treatment groups from the control groups with virtually the same statistical certainty as the SRI. Therefore, it remains to be determined which, if either, of these outcome measures might perform best in future lupus trials. At present, numerous follow-up trials are underway to assess which patient subpopulations and which disease manifestations are responsive to belimumab. At the same time that belimumab was being tested in patients with lupus manifestations other than nephritis, abatacept was being tested in patients with lupus nephritis. A large international trial failed to achieve its primary endpoint. However, post-hoc analyses have raised questions about that result. Specifically, when the data from the abatacept trial were subjected to the outcome measures from other major lupus nephritis trials (LUNAR and ALMS), the complete response (CR) rates among subjects treated with abatacept were substantially higher than the CR rates in the control group [1] . Subsequent analyses of the data from this trial examined the discriminatory capability of other possible outcome measures and demonstrated that, at least in this dataset, the CR rate at 12 months discriminated treatment from control groups more effectively than other common outcome measures (including partial response (PR), overall response (CR+PR), treatment failure rate, or response rates at 6 months rather than 12 months). Studies currently in progress should help to clarify whether abatacept is effective in the treatment of lupus nephritis. 4 , BP Tsao women) and protein (P = 0.009 in men and P = 0.038 in women). PBMCs from heterozygotes exhibited higher G/C allele ratios of TLR7 transcripts 4 hours after incubation with actinomycin D (inhibitor of transcription initiation) (P = 0.04), indicating slower degradation of G allele-containing transcript. The nonrisk allele, but not the risk allele, was predicted to match microRNA-3148 (miR-3148) at the second base in the binding site. Transcript levels of miR-3148 and TLR7 were inversely correlated in PBMCs from 16 SLE patients and 21 controls (R 2 = 0.255, P = 0.001), suggesting miR-3148 modulating TLR7 expression. Overexpression of miR-3148 via transfection into HEK 293 cells led to a more than twofold reduction in luciferase activity driven by the TLR7 3'-UTR segment containing the nonrisk allele than that containing the risk allele (P = 0.001). Conclusion: We identified and confirmed a genome-wide significant association between rs3853839 and SLE susceptibility in 22,613 subjects of Eastern Asian, EA, AA and HS ancestries (P meta = 6.4 × 10 -19 , OR (95% CI) = 1.26 (1.20 to 1.32)). Reduced modulation by miR-3148 confers slower degradation of the risk allele containing TLR7 transcript, resulting in elevated levels of gene products and a more robust type I IFN signature. Background: Aberrant DNA methylation has been implicated in the pathogenesis of systemic lupus erythematosus (SLE), with less DNA methylation observed in SLE patients compared with healthy controls. We sought to determine whether DNA methylation differences are also associated with anti-dsDNA autoantibody production in SLE. Methods: Genomic DNA from peripheral blood leukocytes was isolated from 326 SLE patients, including 158 anti-dsDNA-positive and 168 anti-dsDNAnegative. All SLE cases were female, of European descent, and had never smoked. DNA methylation profiles were initially characterized on a subset of patients (n = 208, with dsDNA-positive cases matched to dsDNA-negative cases on age and disease duration) using the Illumina HumanMethylation27 Beadchip (27 k chip). Subsequently, all patients (n = 326) were characterized for the HumanMethylation450 array, and analyses focused on the most strongly associated regions from the 27 k methylation data. Paired t tests were used to identify site-specific methylation differences associated with anti-dsDNA autoantibody production in the initial phase, with P < 1.8 × 10 -6 (Bonferroni corrected) considered statistically significant. Genome regions that demonstrated statistically significant associations with dsDNA status were further assessed using the 450 k methylation data. Results: Overall, less methylation was observed in anti-dsDNA positive patients compared with dsDNA-negative patients. Analysis of the 27 k methylation data demonstrated decreased methylation of a CpG site near SOCS2 (P = 3.5 × 10 -7 ), an inhibitor of the STAT family of transcription factors, as well as a site near GGT1 (P = 4.3 × 10 -3 ). In addition, increased methylation of two CpG sites in PRIC285, a transcriptional co-activator for nuclear receptors, was significantly associated with anti-dsDNA autoantibody production (P = 1.9 × 10 -7 and 3.4 × 10 -7 ). Subsequent analysis of 114 methylation sites from the 450 k methylation data in these regions demonstrated very strong association with the methylation site cg22764925, located in the 5'-UTR region of GGT1 (P = 2.8 × 10 -11 ), with an average difference of 7.7% between methylation levels of anti-dsDNA-positive and anti-dsDNA-negative patients. The methylation site cg11738543, and several other CpG sites in the SOCS2 gene, were also associated with anti-dsDNA antibody status (P = 4.2 × 10 -8
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Conclusion: These findings suggest that abnormal methylation patterns of specific genes, including GGT1 and SOCS2, may contribute to autoantibody production in SLE. Studies of DNA methylation and other epigenetic modifications may help elucidate biologic mechanisms involved in the pathogenesis of SLE. Background: Differences in access to medications may be related to socioeconomic disparities in outcomes among individuals with systemic lupus erythematosus (SLE). We investigated county-level socioeconomic status (SES) and corticosteroid, hydroxychloroquine and immunosuppressant use among individuals in the low-income US Medicaid population. Methods: From the US Medicaid Analytic eXtract (MAX) data, containing all billing claims from 2000 to 2004, we identified adults, aged 18 to 65, with incident SLE (≥3 SLE ICD-9 codes (710.0), >30 days apart, with 24 months of prior enrollment without SLE claims). Sex, age, race/ethnicity, ZIP code, and geographic region were obtained. We determined health professional shortage areas, number of state-level rheumatologists, and county-level SES using a validated composite of US Census variables. Our outcome measures were use at any time of corticosteroids, hydroxychloroquine, or an immunosuppressant (azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine or tacrolimus). We used multivariable logistic regression to examine relationships between sociodemographic variables and medication prescriptions. Results: Of 3,965 Medicaid enrollees with incident SLE, the mean age was 39.5 ± 12; 94.1% were female, 41.2% African American, 33.7% White, and 15.2% Hispanic. A total of 67.4% received corticosteroids, 49.5% received hydroxychloroquine, and 17.5% received an immunosuppressant. Adjusting for months of enrollment, 77.5% of patients in the lowest SES quartile received corticosteroids compared with 65.9% in the highest (OR = 1.8, 95% CI = 1.27 to 2.58). In our fully adjusted model (Table 1) , increasing countylevel SES among Medicaid enrollees with incident SLE was associated with a lower odds of receiving a corticosteroid prescription, but a higher odds of receiving an immunosuppressant prescription. Hydroxychloroquine use did not vary significantly by SES. Conclusion: In higher SES areas, corticosteroid use among patients with incident SLE appears to be less frequent, while immunosuppressant use Understanding the functionality of lupus susceptibility alleles may best be done using cells of healthy individuals harboring one or two copies of the susceptibility allele. With this approach, confounding variables introduced by disease and medication are avoided. We have studied the SLE susceptibility allele of Blimp-1 in dendritic cells and Csk in B cells. The Blimp-1 risk allele exhibits low expression and leads to an increased secretion of proinflammatory cytokines. The Csk risk allele leads to enhanced expression and an increased response to B-cell receptor signaling. These effects of the risk alleles on activated or resting cells, respectively, provide insight into disease pathogenesis. Systemic lupus erythematosus is a genetically complex autoimmune disease. A large body of evidence suggests an important role for epigenetic variation, particularly DNA methylation changes, in the pathogenesis of lupus. We recently performed a comprehensive evaluation of the DNA methylome in lupus T cells and identified a number of differentially methylated loci that can contribute to the pathogenesis of the disease. By analyzing the interaction between genetic risk, T-cell DNA demethylation, and the SLEDAI scores, we demonstrated that the (genetic risk)/(T-cell DNA methylation) ratio increased directly with disease activity in lupus patients. Furthermore, men with lupus require a higher genetic risk and/or lower T-cell DNA methylation levels to achieve a lupus flare of equal severity to women, suggesting genetic-epigenetic interaction in explaining the sex bias in lupus. We have also established the genetic region containing methylCpG-binding protein 2 (MECP2) as a lupus susceptibility locus. MeCp-2 is a key transcription factor critically involved in regulating the expression of methylation-sensitive genes, and directly recruits DNA methyltransferase 1 (DNMT1). Indeed, recent data from our group demonstrate that the lupusassociated variants in MECP2 induce DNA methylation changes in key inflammatory genes. Our data suggest that efforts to study geneticepigenetic interactions in lupus will further our understanding of the disease pathogenesis and might help to explain, at least in part, the missing heritability in lupus.
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Serum chemokine levels predict flares of disease activity in two independent systemic lupus erythematosus cohorts H Bilgic 1 Background: Gene expression profiling of blood samples from SLE patients has revealed an interferon signature defined by increased expression of type I interferon (IFN)-inducible genes. In lupus patients with quiescent disease, we previously showed that elevated serum levels of IFNinducible chemokines IP-10, MCP-1, and MIP-3b identified a subgroup of patients who were more likely to flare within the following year. The goal of this study was to derive flare risk definitions from the discovery cohort and test those definitions in an independent patient group. Methods: Consenting SLE patients were enrolled in the Autoimmune Biomarkers Collaborative Network (ABCoN) study from the Hopkins Lupus Cohort. Sera were isolated from blood collected in serum-separator tubes. SearchLight multiplexed immunoassays (Aushon Biosystems) were used to quantitate serum levels of IP-10, I-TAC, MCP-1, and MIP-3b. ABCoN Cohort 1 was used for discovery of significant variables for defining flare risk and nonrisk, and those risk definitions were tested in the independent Cohort 2. In 254 patients from Cohort 1 with inactive or mild disease (SLEDAI ≤4) at baseline, we tested serum chemokine levels, the IFN gene score, and clinical laboratory values. Risk definitions were assessed by Kaplan-Meier survival analysis and multivariate Cox regression. Statistically significant markers derived from Cohort 1 were tested in Cohort 2, in which 262 patients had SLEDAI ≤4 at their first study visit. Results: In both cohorts, patients with high chemokine scores (calculated from IP-10, MCP-1, and MIP-3b levels) had an increased frequency of future flare (Cohort 1, Kaplan-Meier P = 0.0001; Cohort 2, P = 0.003). In Cohort 1, individual markers IP-10, I-TAC, MIP-3b, and the IFN gene score identified patients who were more likely to flare (Kaplan-Meier P < 0.05). Risk definitions based on IP-10, I-TAC, and the IFN gene score were also significant in Cohort 2. In multivariate regression analysis, IP-10 and I-TAC were identified as significant predictors of flare (Cohort 1, P = 0.003; Cohort 2, P = 0.04). Conclusion: Measurement of chemokine levels in frozen samples, collected from two longitudinally followed cohorts of SLE patients, identified several chemokines that were associated with development of flare in the subsequent 12-month period of time. A combination of chemokine levels may be used to predict flare risk in SLE and to aid in patient management. Background: Systemic lupus erythematosus (SLE) can cause considerable morbidity during pregnancy. Although several studies have evaluated fetal outcome in lupus pregnancy, only one small study assessed congenital anomalies in 30 children born to SLE mothers, showing no excess risk. In a large population-based study, we aimed to determine whether children born to women with SLE have an increased risk of major congenital anomalies compared with children born to women without SLE. Methods: We identified all women who had ≥1 hospitalization for a delivery after SLE diagnosis using Quebec's physician billing and hospitalization databases (1989 to 2009). Women were defined as SLE cases if they had any of the following: ≥1 hospitalization with a diagnosis of SLE prior to the delivery; a diagnosis of SLE recorded at the time of their hospitalization for delivery; or ≥2 physician visits with a diagnosis of SLE, occurring 2 to 24 months apart, prior to the delivery. We randomly selected a general population control group, composed of women matched at least 4:1 for age and year of delivery, who did not have a diagnosis of SLE prior to or at the time of delivery. We identified children born live to SLE cases and their matched controls, and obtained information on all physician visits and hospitalizations incurred by these children. We ascertained major congenital anomalies, as defined by ≥1 hospitalization or physician visit with an ICD-9/ 10 diagnostic code for major congenital anomaly, within the first 12 months of life. We performed multivariate analyses to adjust for maternal demographics (that is, age, education, marital status), sex and birth order of child, major maternal co-morbidities (that is, pre-gestational diabetes, hypertension, asthma, depression), and relevant maternal medications (that is, antimalarials, corticosteroids, immunosuppressants). Results: A total of 507 women with SLE had 721 children, while 5,862 matched controls had 8,561 children. Compared with controls, children born to women with SLE experienced slightly more major congenital anomalies (13.6% (95% CI = 11.3 to 16.3) vs. 10.4% (95% CI = 9.7 to 11.1)). In multivariate analyses, children born to women with SLE had a substantially increased risk of major congenital anomalies (adjusted OR = 1.28, 95% CI = 1.01 to 1.62) compared with controls. Medication exposures did not seem to mediate the risk of major congenital anomalies. Conclusion: Our findings suggest that, compared with children from the general population, children born to women with SLE have an increased risk of major congenital anomalies, and prompt further research to elucidate this issue. Background: End-stage renal disease (ESRD) is a major cause of morbidity and costs in patients with systemic lupus erythematosus (SLE). Patients with proliferative lupus nephritis are at greatest risk of ESRD, but with recent treatment advances, the proportion of patients with proliferative nephritis who develop ESRD may be decreasing. We sought to learn the risk of ESRD in patients with proliferative lupus nephritis enrolled in studies since 1990. Methods: In a systematic literature review, we searched PubMed, Embase, and the Cochrane Database of Systematic Reviews from inception to November 2011 to identify published articles on the risk of ESRD in lupus nephritis. We also searched references of retrieved articles and reviews. We excluded articles with fewer than 10 patients, less than 1 year of follow-up, those primarily of children, and those that did not report ESRD (dialysis or renal transplantation) as a specific outcome. Of 1,144 unique articles from the searches, we did a full-text review of 373 articles. One hundred and fifty-five articles met inclusion criteria, reported relevant data and were not duplicate reports on the same cohort. Thirty-one studies began enrollment in 1990 or later. Here we examined the 14 studies (15 arms) that reported outcomes of patients with proliferative lupus nephritis. We computed weighted averages of the proportion with ESRD at the mean follow-up. For studies with more than one treatment arm, we pooled estimates across arms. Results: The 15 arms were from one prospective observational study, five retrospective observational studies, and nine clinical trials. Samples ranged from 9 to 117 patients. All but one study were done at referral centers, and nine specifically excluded patients with elevated serum creatinine at baseline. Mean serum creatinine at entry was 1.2 mg/dl and mean proteinuria was 3.0 g/day. Mean duration of lupus nephritis at entry was 1.1 years. Mean follow-up was 4.5 years. At 1 to 3 years of lupus nephritis, the pooled estimate of ESRD was 4.5% (based on five arms); at 4 to 6 years, the pooled estimate was 6.9% (three arms); at 7 to 9 years, the pooled estimate was also 6.9% (five arms); and at 10 to 11 years, the pooled estimate of ESRD was 3.9% (two arms).
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Conclusion:
In patients with proliferative lupus nephritis enrolled in studies since 1990, the risk of ESRD over the first decade of lupus nephritis is under 7%. This estimate is largely based on long-term followup of clinical trials and studies that excluded patients with renal insufficiency at baseline.
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Impact of systemic lupus erythematosus organ damage on unemployment or disability from a population-based cohort
SS Lim
Background: Systemic lupus erythematosus (SLE) predominantly develops in younger age groups, when many are establishing themselves in the workforce. The development of a chronic, autoimmune condition during this period can have a devastating impact on employment. The objective was to determine the impact of different organ damage in patients with SLE on employment loss from a large, population-based cohort.
Methods: The source of data was from the 2011 to 2012 annual patientreported survey of the Georgians Organized Against Lupus (GOAL) Study, an ongoing population-based cohort of patients with validated SLE in Atlanta, GA assembled primarily from the Georgia Lupus Registry (GLR). The GLR was supported by the Centers for Disease Control and Prevention and designed to more accurately estimate the incidence and prevalence of SLE. In partnership with the state health department, the GLR was able to access protected health information without patient consent. GOAL Study participants were surveyed regarding employment status at the time of survey completion along with other demographic information. Organ damage was measured using the Brief Index of Lupus Damage. Disease activity was measured using the SLE Activity Questionnaire (SLAQ). Logistic regression analysis was used to measure the association between categories of organ damage and unemployment/disability. Results: A total of 459 SLE patients were surveyed with a mean age of 46.5 (SD ± 10), 13.4 (SD ± 8.6) years of disease, and 14.2 (SD ± 2.8) years of education; 93.2% were female, 79.5% were black and 14.4% white. One hundred and ninety-seven (42.9%) were working and 262 (57.1%) were unemployed/disabled. The median duration of loss of employment was 7.1 years (IQR 3.1 to 12.3). See Table 1 . Conclusion: In total, 57.1% of SLE patients were unemployed or disabled at the time of the survey. Organ damage from SLE has a profound association with unemployment/disability. In the multivariate model, low education level and depression were independently associated with unemployment/disability. In line with other studies, cardiovascular and renal damage were associated with unemployment/disability. Previous studies have not reported disease activity (SLAQ) as a mediator and Background: Infection is a prominent cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). The proportion of hospitalizations in patients with SLE due to preventable infections is unknown. The objectives of this study were to: determine the proportion of hospitalizations in SLE patients due to preventable infections; and determine whether preventable infections are associated with lengths of stay ≥14 days or mortality. Methods: This study was a retrospective cohort study using a provincial administrative dataset of hospitalizations (Discharge Abstract Database (DAD)) in Alberta, Canada. A total of 1,626 SLE patients with hospitalizations during fiscal years 2002 to 2009 were identified from the DAD using the International Classification of Diseases-10-CA (ICD-10-CA) code M32.x. Outcome measures of preventable infections (influenza, Streptococcal pneumonia, tuberculosis and unspecified pneumonia) were identified during readmissions in 2009/10 using ICD-10 codes. Comparisons between admissions with and without infections were computed using admission and patient characteristics: Student's t test and the Wilcoxon rank-sum tests were used for continuous variables and the chi-square test was used for categorical variables. Generalized estimating equation models were constructed to examine associations between infections and the outcomes of long length of stay (dichotomized to ≥14 or <14 days) and mortality. Results: In total, 312 SLE patients had 504 admissions in 2009/10. Preventable infections accounted for 9.3% of all admissions. Patients with infections had similar demographic characteristics and co-morbidities compared with those without infections with the exception of chronic pulmonary diseases that were more common in those with infections (41.4% vs. 18.3%, P = 0.003). Hospitalizations with preventable infections were associated with longer median length of stay (7.5, IQR 4.4 to 23.6 days vs. 4.7, IQR 2.3 to 11.0 days, P < 0.001) and higher mortality rates (12.8% vs. 5.5%, P = 0.047). Generalized estimated equations revealed that infections were associated with length of stay ≥14 days (OR = 2.59, 95% CI = 1.31 to 5.11, P = 0.006) but not mortality (OR = 2.13, 95% CI = 0.81 to 5.62, P = 0.128). Conclusion: Nearly one in 10 admissions in SLE patients previously hospitalized are due to or complicated by preventable infections. The preventable infections are associated with an increased length of stay and therefore greater resource utilization. These results highlight the importance of preventative vaccinations in SLE patients. Further studies are warranted to determine where gaps in vaccination and infection prevention occur in this population. Acknowledgements: CEB is supported by a research fellowship from Alberta Innovates Health Solutions and a postgraduate rheumatology fellowship from UCB-CRA-TAS (UCB Pharma, Canadian Rheumatology Association and The Arthritis Society). Background: An increased lung cancer risk in SLE has been suggested in the literature [1] . Our objective was to provide an updated analyses of the lung cancer cases from a multi-site international cohort study, including descriptive statistics of the demographics (age, sex, and race/ ethnicity) of cases, as well the of histology. Methods: Data from an SLE sample of 15,980 SLE patients from 28 centers were analyzed (in Canada, the United States, the United Kingdom, Denmark, Sweden, Scotland, Korea and Iceland). Information on date of birth, sex and race was available, along with the date of SLE diagnosis. Cancer occurrence was ascertained through linkages with regional tumor registries. We assessed the demographic characteristics for all lung cancer cases in the SLE patients, and information on histology types was analyzed from the centers where this information was available.
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Results: In the current analyses, 101 lung cancer cases that had occurred after SLE diagnosis were studied. The lung cancer cases were distributed across 21 centers. The average age of the SLE patients at lung cancer diagnosis was 60 years (median 40, standard deviation (SD) 10.9). The average SLE duration at the time of lung cancer diagnosis was 13 years (median 12, SD 10.6). Race/ethnicity was not provided by six centers (35 cases). Of the remaining 66 cases, the majority were Caucasian (n = 54, 53.5%) followed by nine African-American, one Asian, one Pacific-Islander and one of unknown racial/ethnic origin. Histological lung cancer type was only provided by 12 centers (59 cases). The most common histological type reported within these 59 cases was squamous cell carcinoma (n = 15, 25.4%; 95% CI = 16.1 to 37.8) followed by adenocarcinoma (n = 13, 22%; 95% CI = 13.4 to 34.1) and nonsmall-cell carcinoma (n = 5, 8.5%; 95% CI = 3.7 to 18.4). The remaining 44% were composed of carcinomas not otherwise specified and a variety of uncommon tumors: large cell, clear cell, solid, bronchoalveolar, adenosquamous, epithelial hemangioendothelioma, oat cell, carcinoid, small cell and mucinous histological types. Conclusion: In the general population, about 30 to 40% of lung cancer cases are adenocarcinoma, with 20 to 30% squamous cell carcinoma, and 10% large cell carcinoma [2] . Our results suggest a similar distribution, but with a possibly lower proportion of adenocarcinomas, and a higher number of uncommon lung cancer types. Further work is planned to assess other features of these cancers. Background: We recently evaluated the risk of malignancy in SLE by linking a multi-site international SLE cohort with regional tumor registries. Across 28 centers, 15,980 patients were observed for 119,846 (average 7.5) personyears. In total, 641 cancers occurred, for an overall standardized incidence ratio (SIR) of 1.14 (95% CI = 1.06 to 1.24). Hematologic malignancies were substantially increased (SIR = 3.01, 95% CI = 2.47 to 3.62), particularly nonHodgkin's lymphoma (NHL; SIR = 4.36, 95% CI = 3.43 to 5.47) and leukemia (SIR = 1.76, 95% CI = 1.04 to 2.78) [1] . Yet the relative influence of treatment versus disease activity is unknown. Our objective was to determine the relative importance of drugs versus disease activity in mediating the increased risk of lymphoma.
Methods: We performed case-cohort analyses within this multi-site SLE cohort. Adjusted hazard ratios (HRs) for lymphoma were generated in multivariate regression models, for time-dependent exposures to immunomodulators (cyclophosphamide, azathioprine, methotrexate, mycophenolate, antimalarials, glucocorticoids), disease activity (mean adjusted SLEDAI-2K), demographics, calendar year, Sjögren's syndrome, and SLE duration. Partially adjusted models were also performed, using only covariates whose HR CI excluded the null. Sensitivity analyses were performed, lagging cyclophosphamide exposures by 5 years. Medications were treated both categorically (ever/never) and as cumulative doses.
Results: We studied 64 lymphomas (61 NHL, three Hodgkin's) and 4,739 cancer-free controls. As in the general population, lymphoma risk in SLE was higher in males and with age. Lymphomas occurred a mean of 13.1 years (standard deviation 9.8) after SLE diagnosis. Univariate analyses suggested a decreased lymphoma risk within the highest tertile of disease activity (relative to those with the lowest activity) but in fully adjusted models (using all variables listed above), the CI included the null (Table 1) . Sensitivity analyses, lagging cyclophosphamide exposures, yielded similar results. In a partially adjusted model (retaining age and highest tertile of disease activity), the HR suggested a twofold lymphoma risk after cyclophosphamide. Despite a trend towards greater cyclophosphamide use in cases versus controls, in fully adjusted models, no drug was estimated to be an independent risk factor. Still, due to correlation, it remains difficult to differentiate the effects of medications from disease activity.
Conclusion:
We did not definitively demonstrate an increased risk for any medications, despite a trend to greater cyclophosphamide use in the lymphoma cases. If anything, we noted a protective effect for very high SLE disease activity. Further work will focus on genetic profiles that might interact with medication exposures to influence lymphoma risk in SLE. Background: Little is known about the quality of healthcare delivered to patients with lupus nephritis in the United States and the major determinants of quality remain unknown. We aimed to examine the sociodemographic, geographic, and healthcare system factors associated with performance on a healthcare quality measure in a nationwide cohort of Medicaid recipients with incident lupus nephritis. Methods: We used US Medicaid analytic extract (MAX) data from 2000 to 2004 containing person-level files on Medicaid eligibility, utilization and payments. We identified patients meeting a validated administrative data definition of incident lupus nephritis, and used this group as the denominator population for the quality metric (QM). The QM numerator assessed receipt of induction therapy with glucocorticoids and another immunosuppressant (azathioprine, mycophenolate mofetil, mycophenolic acid, cyclophosphamide, cyclosporine A, or tacrolimus) within 90 days of lupus nephritis onset. Patients with end-stage renal disease were excluded. We used multivariable logistic regression models to examine sociodemographic (age, sex, race/ethnicity), geographic (US region), and healthcare (health professional shortage areas, HPSAs, from the Area Resource File) predictors of higher performance. We also examined the restrictiveness of Medicaid benefits in each state, defined by less generous medication coverage policies (mandatory generic substitution, requirements for prior authorization and drug co-payments), and whether the patient's usual source of care was the emergency department or the ambulatory setting (>50% visits).
Results: A total of 974 Medicaid recipients met the definition of incident lupus nephritis. The mean age was 39 years (SD 12), 93% were female, and most were African American (African American 48%, White 27%, Hispanic 13%, Asian 6%). Individuals were geographically dispersed (20% Midwest, 22% Northeast, 34% South, 24% West), and 95% resided in partial or complete HPSAs. One hundred and sixty-four individuals resided in states with more restrictive Medicaid benefits. At 90 days, only 16% of patients met all numerator components of QM1; 45% of individuals received only steroids (mean prednisone dose 28 mg/day), and 3% received an immunosuppressant alone. Among those treated with an immunosuppressant, 31% received azathioprine, 47% received mycophenolate, 14% received cyclophosphamide, and 11% received a calcineurin inhibitor. For 20% (n = 192) of patients, the usual source of care was in the emergency setting. In multivariable logistic regression models, younger individuals were more likely to receive optimal treatment (OR for 18 to 34 years vs. 51 to 64 years = 3.5, CI = 1.6 to 7.6), while those living in the South and Midwest were less likely (OR = 0.49, CI = 0.24 to 0.67 and OR = 0.30 CI = 0.15 to 0.61, respectively). Those whose usual source of care was the emergency department were less likely to receive optimal treatment (OR = 0.47, CI = 0.28 to 0.81). In this adjusted analysis, we did not find significant associations for race/ethnicity, HPSA or Medicaid restrictiveness with QM performance. Conclusion: Most US Medicaid recipients with incident lupus nephritis in our study did not receive timely induction therapy, and many were treated with high-dose steroids alone. We found significant geographic variation in performance, with the South and Midwest having lower performance than other regions. A substantial number of Medicaid patients with lupus nephritis used the emergency department as a usual source of care and performance on the QM is lower in this setting. These data suggest a need for targeted quality improvement interventions, including increasing access to appropriate ambulatory care for Medicaid recipients with lupus nephritis. Results: Upon enrollment into the cohort the proportion of NP events attributed to SLE varied from 19 to 38% and affected 6.1 to 11.7% of patients, depending upon the stringency of the attribution rule. Seizure disorders, cerebrovascular disease, acute confusional states and neuropathies were the most common of the 19 NP syndromes. Changes in SF-36 summary and subscale scores, in particular those related to mental health, were strongly associated with physician assessment of clinical outcomes of NP events. The short-term outcome of NP events was determined by their characteristics and attribution: focal events and those attributed to SLE had better outcomes. Overall, NP events had a negative impact on self-report health-related quality of life (HRQoL) but this was not necessarily true for all types of NP events. For example, most seizures were attributed to SLE, resolved in the absence of anti-seizure medications and were not associated with a persistent negative impact on HRQoL.
The clinical and epidemiological challenge imposed by the high frequency and diversity of NP events in SLE patients can be addressed through the application of composite attribution rules, as well as physician and patient-derived outcome measures. Background: Local seafood is a dietary staple among the African American Gullah population of South Carolina. High levels of persistent organic pollutants (POPs) have been found in local bottlenose dolphins, sentinel species for human health and consumers of many of the same fish as the Gullah. Links have been established between these bioaccumulating, ubiquitous compounds and deleterious health effects in humans. The objective was to determine whether levels of POPs, specifically perfluorinated compounds (PFCs), correlate with fish intake and markers of immune dysfunction in genetically at-risk individuals. Methods: At the onset of the Persistent Organic Pollutants in AutoImmunity (POPAI) study, one-on-one interviews were conducted with Gullah community members to validate a comprehensive environmental exposure questionnaire. The validated questionnaire, including a seafood intake survey, was then administered prospectively to patients with lupus, firstdegree relatives of lupus patients, and unrelated nonlupus controls participating in the SLE in Gullah Health (SLEIGH) study. PFC levels (PFOS, PFOA and PFNA), antinuclear antibody titers and other autoantibodies were measured in the serum of participants drawn at the time of their study visit. Results: Seafood intake questionnaires received from 103 Gullah participants enrolled in the SLEIGH study found 57% consumed locally caught seafood at least once a month and 40% consumed species known to contain high levels of POPs in the Charleston Harbor area. Preliminary results from 33 Gullah controls show that all have measurable serum levels of PFCs (specifically PFOS, PFOA and PFNA) from baseline and follow-up visits 7.3 ± 1.4 years apart, with annual servings of seafood directly correlating with serum PFOS and PFNA (p = 0.02 and 0.03). ANA positive controls (48% at baseline) had higher mean levels compared to ANA negative controls for PFOS (75.1 vs 48.2 ng/ml, p = 0.06), PFOA (7.0 vs 5.8, p = NS) and PFNA (3.2 vs 2.1, p = 0.04). Conclusion: These ongoing studies address concerns of the Sea Island Gullah community regarding the potential immune health effects of the bioaccumulating pollutants found in local dietary staples such as fish.
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Rising prevalence of systemic autoimmune rheumatic disease: increased awareness, increased disease or increased survival? CA Peschken Methods: In a stable population of over 900,000 adults, we used hospital and physician claims from a large administrative database using two different case definitions for the 5-year period prevalence of SARD from 1995 to 2010. For each 5-year interval, the mid-year population was used as the denominator. For physician claims, we identified SARD using The International Classification of Diseases (ICD)-9 Code 710. For hospital claims we identified SARD using the ICD-9 Code 710 from 1995 to 2004, and the ICD-10 Code M32 from 2004 onwards. Two case definitions were used: ≥5 claims ever for SARD by any physician, or ≥2 SARD claims ≥2 months apart from a specialist within the 5-year period. Prevalence rates by age (18 to 30; 31 to 50; and >50 years) and sex were calculated. The healthcare database was linked with a prescription database, and the proportion of patients treated with glucocorticoids, antimalarials and immunosuppressives was calculated. Results: The prevalence rate for SARD ranged from 0.08 to 0.013% in 1995 to 2000, and rose to 0.13 to 0.16% in 2005 to 2010, depending on the case definition of SARD. Prevalence rates for females aged >50 rose from 0.25% in 1995 to 2000 to 0.36% in 2005 to 2010, while all other age and sex groups remained stable (Figure 1) . The proportion of patients receiving glucocorticoid prescriptions declined slightly from 64% in 1995 to 60% in 2010, while the proportion of antimalarial, moderate and severe immunosuppressive prescriptions increased: 43 to 56%; 24 to 44%; and 3.6 to 6.6% respectively. Rheumatology manpower in the region doubled from 0.47 to 1.2/100,000 from 1995 to 2010. Conclusion: We found a rise in the prevalence of SARD over the 15-year period. This may reflect improved survival, given the rising rate in females >50, or improved ascertainment due to increasing awareness of SARD among physicians, and increased rheumatology manpower. This study also illustrates changing treatment patterns with less use of glucocorticoids and greater use of antimalarials and immunosuppressives, which may contribute to improved survival. Further attempts at determining diagnostic accuracy and disease outcomes in this population using linkages with clinical databases are underway. Background: Women with systemic lupus erythematosus (SLE) have increased rates of subclinical atherosclerosis and cardiovascular (CV) events [1, 2] . Circulating adhesion molecules (CAMs) have been associated with subclinical atherosclerosis in SLE patients [3, 4] . We investigated the significance of CAMs in subclinical atherosclerosis progression, as measured by the coronary artery calcium score (CAC) and aorta calcium score (AS) in women with SLE. Methods: Baseline data collected include demographics and circulating adhesion molecule levels. SLE factors collected included modified SLICC/ ACR-DI Damage Index (SDI) (excluding CV outcomes). CAC and AS were measured by electron beam or multidimensional computed tomography at baseline and at one follow-up visit in the Study of Lupus Vascular and Bone Long-Term Endpoints (SOLVABLE). High-risk CAC and AS were defined as CAC >10 and AS >100, respectively. Progression in CAC and AS at follow-up was defined as CAC >10 or AS >100 and >10% increase from baseline. Univariate regression models of CAC and AS with risk factors were examined, and further adjusted for age. CAMs measured were ICAM-1, VCAM-1, soluble E-selectin (sESEL), and CD40L. Results: Imaging at baseline and follow-up were performed on 142 subjects; baseline AS scans were not performed in 36 subjects (Table 1) . Adhesion molecule levels ( Table 2 ) and imaging marker progression (Table 3 ) results are presented. In age-adjusted models, only sESEL was significantly associated with AS and CAC progression (Table 4 ). Conclusion: A higher level of sESEL is associated with progression in AS and CAC in women with SLE. While previous studies have shown CAMs association with subclinical atherosclerosis [3, 4] , these results suggest sESEL may predict progression of subclinical atherosclerosis, as measured by AS and CAC, in women with SLE. Objective: α-chlorofatty acid (α-ClFA) is one product of myeloperoxidase activity in vivo during atherogenesis [1] . Our study investigates whether serum α-ClFA may be a biomarker for subclinical cardiovascular disease (CVD) in patients with systemic lupus erythematosus (SLE). Methods: One hundred and eighty-five women with SLE and 186 controls participated in this ancillary study of the Study of Lupus Vascular and Bone Long-term Endpoints (SOLVABLE). Data collection included demographic information, CVD and SLE risk factors, and baseline laboratory assessments. α-ClFA was measured in stored serum by liquid chromatographyelectrospray ionization mass spectrometry with selected reaction monitoring detections. Each sample was run in triplicate. Coronary artery calcium (CAC) and aorta calcium (AC) were measured by electron beam computed tomography or multi-detector computed tomography. Calcium scores were calculated using the Agatston method. Outcome measures were the presence of higher risk CAC or AC scores (CAC >10 or AC >100) versus lower risk scores (CAC ≤10 or AC ≤100) [2] . Significant associations were identified with descriptive characteristics, univariate, and multivariate analyses. Results: Cases had higher baseline levels of α-ClFA than controls (42.2 ± 19.2 fmol/μl vs. 34.5 ± 10.9 fmol/μl, P = 0.014). Cases with lower risk CAC and AC scores had statistically higher levels of α-ClFA compared with controls, while cases and controls with higher risk CAC and AC scores had similar α-ClFA levels (Table 1) . In multivariate analyses, SLE had the strongest independent association with higher risk CAC scores, followed by dyslipidemia and age (Table 2) . SLE also had the strongest association with higher risk AC scores, followed by history of tobacco use, age, and C-reactive protein level (Table 3) . α-ClFA was not independently associated with higher risk CAC or AC scores. Conclusion: SLE had the strongest independent association with the presence of higher risk subclinical CVD, while serum α-ClFA levels were not independently associated at baseline. Acknowledgements: This research was supported by R21-HL098907, UL1-RR025741, K24-AR02318, P60-AR30692, P60-AR48098, M01-RR00048, and T32-AR07611 through the Background: Accumulating data indicate that inappropriate activation of type I interferon (IFN) plays a key role in the pathogenesis of systemic lupus erythematosus (SLE). Given that IFN can influence B-cell lymphopoiesis in murine bone marrow (BM), we explored the hypothesis that IFN activation in SLE BM has direct effects on B-cell development. Additionally, the impact of B cells on pDC production of IFN was examined. + , IgD -switch memory B cells. SLE patients with a BM IFN signature were enriched for a high number of autoantibody specificities (P = 0.003 compared with IFN low), and the degree of IFN activation in the BM correlated with peripheral lymphopenia (P = 0.019) and disease activity (P = 0.05). In order to understand the etiology of IFN activation in SLE BM, we examined the production of IFN by pDCs. CpG induced IFN production in pDCs in a dose-dependent fashion. Notably, a higher proportion of BM pDCs produced IFN compared with paired PB. Moreover, pDCs produced 59% more IFN in the presence of B cells. Conclusion: This is the first demonstration of an IFN signature in SLE BM. These results suggest that the BM is an important but previously unrecognized target organ in SLE with critical implications for B-cell ontogeny and selection. We postulate that in the setting of IFN activation the stringency of negative selection of autoreactive B cells in the BM may be reduced. Circulating immune complexes and apoptotic fragments in SLE BM may serve as ligands for Toll-like receptors on pDCs contributing to aberrant IFN production and, in turn, B cells may be critical regulators of pDC function. Acknowledgements: Work supported by grants from the NIH (R01 AI077674 and P01 AI078907) and the Rochester Autoimmunity Center of Excellence. Introduction: Antinuclear antibodies can be detected in up to 25% of the population; however, only 5 to 7% are afflicted with an autoimmune disease. Therefore, many individuals are capable of mitigating the presence of autoantibodies and avoiding clinical disease. The objective of this study was to investigate unique features of SLE patients compared with autoantibody-positive (aAb + ) healthy immune systems and to examine roles that cytokines play in maintaining immune equilibrium in ANA-positive healthy individuals. Methods: Individuals (n = 790) were screened by multiplex, bead-based assays for autoantibodies against: dsDNA, chromatin, ribosomal P, SS-A/Ro, SS-B/La, Sm, Sm/RNP, RNP, SCL-70, Jo-1, and centromere B. Sera from aAb + individuals, matched aAb -controls and SLE patients were tested for 52 cytokines using multiplex bead-based assays and ELISAs. Hierarchical clustering was performed and Kruskal-Wallis tests with Dunn's multiple comparisons were compared including a false discovery rate. Immune cell phenotyping and phospho-flow cytometry was performed on peripheral blood mononuclear cells from aAb + and aAb -healthy individuals. Unpaired t tests and Mann-Whitney tests were performed. Results: Of the screened individuals, 57 individuals were positive for at least one autoantibody (7.2%), with 33.3% being Native American, 57.9% European American, 8.8% African American, and 89.5% female. European American aAb + healthy individuals (n = 31) and matched aAb -healthy controls and SLE patients were selected for further analysis. While aAb + healthy individuals displayed some similar cytokine patterns to SLE patients, they also displayed a suppressed cytokine profile that included decreased T-cell cytokines (IFNγ (P < 0.05), IL-5 (P < 0.05), IL-17F (P < 0.01)), decreased B-lymphocyte stimulator levels (P < 0.05), and increased IL-1 receptor antagonist levels (P < 0.001). An increased percentage of B cells was found in aAb + healthy individuals compared with aAb -healthy controls (P = 0.039) that consisted of an increased percentage of memory B cells (P = 0.034) and a decreased percentage of transitional B cells (P = 0.028). Compared with aAb -healthy controls, B cells from aAb + healthy individuals showed significantly increased pSTAT1 and pSTAT3 in response to IFNα stimulation (P = 0.037 and P = 0.040), increased pSTAT1 in response to IFNγ stimulation (P = 0.018), and increased pSTAT3 in response to IL-21 stimulation (P = 0.041). CD4 + T cells from aAb + healthy individuals showed decreased pSTAT3 in response to IFNγ and IL-2 stimulation (P = 0.018 and P = 0.005). IFNα, IFNγ and IL-6 stimulation significantly increased pSTAT signaling in monocytes from aAb + healthy individuals. Conclusion: Although aAb + healthy individuals exhibit features of inflammation and loss of immune tolerance, they are capable of suppressing these responses by regulatory mechanisms probably no longer functional in patients with autoimmune disease.
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Regulatory natural autoantibodies suppress inflammation and SLE disease activity [1, 2] . Furthermore, in vivo administration blocks the development of inflammatory autoimmune disease in experimental murine models [2] . We therefore explored the mechanistic basis for these properties and assessed for potential clinical relevance. Methods: Bone-marrow-derived myeloid DCs and macrophages were stimulated with TLR agonists or with immune complexes (ICs) composed of IgG-autoantibody-chromatin or IgG-autoantibody-RNA. We then evaluated production of inflammatory cytokines, and expression of co-stimulatory molecules, which are markers of DC activation. MAPK activation was evaluated by phospho-flow and immunofluorescence microscopy. In a cohort of 120 SLE patients, we examined the relationships between levels of IgM natural autoantibodies to apoptosis-associated antigens, with lupusassociated autoantibodies and features of disease. Results: In mechanistic studies, during responses to TLR agonists, anti-AC IgM decreased DC activation of the primary MAPKs; ERK1/2, JNK, and particularly p38. This inhibitory response was linked to anti-inflammatory signaling events dependent on nuclear localization of MAPK phosphatase-1, a factor known to also mediate glucocorticoid suppression of immune responses. Anti-AC NAb IgM also suppressed both DNA-IC-induced and RNA-IC-induced cytokine production, and upregulation of CD86 and CD40 on DCs. IgM anti-AC NAb also suppressed IC-mediated MAPK activation [3] . In clinical surveys, IgM autoantibodies to apoptotic cell membranes were commonly detected in healthy humans and SLE patients. In SLE patients, we found that IgM anti-AC levels were significantly higher in patients with low disease activity and less organ damage (by SELENA-SLEDAI, the physician's evaluation and the SLICC damage score). Furthermore, IgM anti-AC levels were also significantly higher in patients without cardiovascular events. In contrast, IgM anti-cardiolipin and IgM anti-dsDNA were significantly higher in patients without renal disease [4] . Background: We have previously shown that B6 mice with an introgressed homozygous NZB chromosome 1 (c1) interval (70 to 100 cM) develop high titers of antinuclear antibodies and severe glomerulonephritis. Using subcongenic mice with shorter c1 intervals, we found that expansion of T H 1, T H 17, and T FH cells was closely associated with the severity of glomerulonephritis. The same expansions were observed using ovalbumin (OVA) as an exogenous antigen, indicating that this was an intrinsic aspect of their immune system. Here we have investigated the role of T cells and dendritic cells (DC) in this expansion. Methods: OVA-specific T cells from B6 or c1 congenic OT-II TCR transgenic mice were adoptively transferred into B6.Thy1.1 or c1(70-100).Thy1.1 mice. The mice were immunized with OVA emulsified in CFA, sacrificed 2 weeks later, and the proportion of various splenic T-cell subsets determined by flow cytometry, gating on Thy1.2 + (transferred) T cells. Bone marrowderived DC isolated from 8-week-old c1(70-100), c1(88-100) and c1(96-100) congenic and B6 control mice were cultured in the presence of LPS, imiquimod and CpG, or pulsed with OVA and co-cultured with naïve OT-II T cells. Production of cyto/chemokines (IL-12, IL-23, IL-6) by stimulated DC was analyzed by ELISA or flow cytometry. Results: Adoptive transfer experiments revealed that the increased IFNγ and IL-17 secreting cell differentiation in c1(70-100) congenic mice arises in part from intrinsic T-cell defects localizing to the NZB c1 96 to 100 and 88 to 96 intervals, respectively. However, OT-II T cells from all mouse strains examined demonstrated enhanced differentiation to T H 1, T H 17, and T FH populations when transferred into c1(70-100).Thy1.1 as compared with B6.Thy1.1 mice. Since DC play an important role in the antigen presentation and cytokine secretion that directs T-cell responses, DC function was contrasted in the various mouse strains. Following TLR stimulation, DC from c1(70-100) mice expressed significantly higher levels of MHC and co-stimulatory molecules, and secreted higher amounts of proinflammatory cytokines such as IL-6 and IL-12. Consistent with altered DC function, OVA pulsed DC from c1(70-100) mice induced significantly increased differentiation of naïve OT-II cells to IFNγ, IL-17 or IL-21 secreting cells as compared with B6 DC. Conclusion: Our results suggest that a genetic polymorphism in the 70 to 100 interval of NZB c1 congenic mice alters DC function and acts together with intrinsic T-cell defects that map to the 88 to 100 interval to promote the expansion of T H 1, T H 17 and T FH cells in c1(70-100) mice. Protein phosphatase 2A is a ubiquitously expressed serine/threonine phosphatase that regulates a large number of cellular processes. Levels of the catalytic subunit of PP2A (PP2Ac) are tightly controlled. T cells from patients with systemic lupus erythematosus (SLE) express abnormally high levels of PP2Ac. This is promoted by a lupus-associated SNP and by DNA hypomethylation that alters local transcription factor binding. PP2Ac regulates CREB, Elf-1, and SP1, and could thus contribute to several molecular abnormalities described in SLE T cells. In order to determine whether increased levels of PP2Ac in T cells play a role in the development and/or promotion of autoimmune disease, we genetically engineered a mouse to transgenically express high levels of PP2A in T cells. This isolated abnormality allowed us to evaluate the effects of PP2Ac dysregulation in an otherwise normal immune system. PP2Ac transgenic (Tg) mice developed modest splenomegaly and lymphadenopathy, but no overt signs of autoimmunity. Susceptibility of PP2Ac Tg mice to immune-mediated disease was evaluated by antibodyinduced glomerulonephritis. Glomerular damage and proteinuria were significantly more severe in PP2Ac Tg mice than in nontransgenic littermates. To determine the mechanism underlying increased kidney damage, we analyzed cytokine production by T cells from PP2Ac Tg and control mice. Production of IL-17 was increased~10-fold in Tg mice. This phenomenon was documented in vitro and in vivo and was pathologically relevant since blockade of IL-17 abrogated the enhanced susceptibility to glomerulonephritis of Tg mice. These results indicated that increased PP2Ac levels enhance the production of IL-17 in T cells and, through this mechanism, promote immune-mediated organ damage. To determine the molecular pathways through which PP2Ac enhances IL-17 production, we analyzed differentiation of CD4 T cells into effector subsets (that is, Th1, Th2, Th17). Although IL-17A and IL-17F production were constantly higher in PP2Ac Tg T cells, other Th17 characteristics did not differ between Tg and control T cells suggesting that the IL-17-inducing effect occurred independently of Th17 differentiation. Analysis of the Il17 locus demonstrated that PP2Ac overexpression was associated with local permissive epigenetic changes (increased histone 3 acetylation), which explained enhanced IL-17 production. We provide evidence that supports dysregulation of PP2Ac in T cells is able to facilitate autoimmune disease by promoting the production of IL-17. This effect is independent of Th17 differentiation and is explained by the capacity of PP2Ac to modify chromatin accessibility at the Il17 locus by inducing defined epigenetic modifications. The mitochondrial adaptor protein MAVS (also known as IPS1, VISA or CARDIF) is a key intermediary in the RIG-I pathway, where viral RNA triggers a conformational change in RIG-I, leading to MAVS activation and activation of IKK and TBK1, with subsequent interferon production driven by IRF-3 and NFB activation and translocation. A recent report using in vitro methods demonstrated that MAVS may form large prion-like aggregates which might stimulate IFN-I activation in a potent and prolonged fashion [1] . We wondered whether such aggregates might be detectable ex vivo in SLE patients, and whether they might play a role in the sustained increased production of IFN-I. The aim was to determine whether aggregated MAVS protein is present in blood cells from SLE patients. Methods: Peripheral blood mononuclear cells (PBMC) were isolated from 17 patients fulfilling ACR criteria for SLE, and from nine controls. Thirty million PBMC were lysed and pellets loaded onto semi-denaturing detergent vertical 1.5% agarose gels. After electrophoresis, the proteins were transferred to Immobilon membranes for immunoblotting with anti-MAVS antibody or anti-β-actin. Results: Six of 17 SLE patients showed clear MAVS aggregation, with essentially all of their MAVS protein in a high-molecular-weight form. None of nine controls had abnormal MAVS. Three of the four SLE patients had nephritis and the fourth had lung involvement. SLEDAI scores of MAVSaggregate positive SLE patients did not differ from patients with normal molecular weight MAVS. Patient 4 (P-4) shows the aggregated MAVS phenotype in the western blot (Figure 1) . MAVS immunoblotting is shown in panel B and actin immunoblotting in panel C. N-1 and N-2 are normal controls. P-1 has less protein loaded and no MAVS band is discernible. Conclusion: This is the first report of aggregated MAVS in human cells. The relationship of this abnormality to disease needs further investigation, but suggests the possibility that prolonged and increased IFN-I production could result from MAVS aggregation, with the formation of poorly degradable prion-like protein that could signal IFN-I production for prolonged periods. Joint linkage and association analysis from multiple laboratories have identified and confirmed polymorphisms in the interferon regulatory factor 5 (IRF5) gene that are statistically associated with susceptibility to systemic lupus erythematosus (SLE). IRF5 SNPs and genetic variants have been consistently replicated and shown to confer risk for or protection from the development of SLE. IRF5 expression is significantly upregulated in SLE patients and upregulation associates with IRF5-SLE risk haplotypes. IRF5 alternative splicing has also been shown to be elevated in SLE patients. Given that human IRF5 exists as multiple alternatively spliced transcripts, each with potentially distinct function(s), it is important to determine whether the IRF5 transcript profile expressed in healthy donor immune cells is different from that expressed in SLE patients. Moreover, the exact functional consequence of an IRF5-SLE risk haplotype on the profile of IRF5 transcripts expressed needs to be addressed. Using a combination of standard molecular cloning techniques and recent advances in nextgeneration sequencing technologies, we examined the profile of IRF5 transcripts expressed in purified immune cells of healthy donors and SLE patients. By enriching for IRF5, we obtained an unprecedented coverage depth >3,000-fold per sample. Molecular cloning was used to generate a full-length IRF5 variant transcriptome for the analysis of IRF5 transcript expression in primary immune cells of SLE patients and healthy donors. This method of analysis was compared with other methods that do not rely on the knowledge of an IRF5 transcriptome; that is, using junction counts and de novo junction discovery. Data from these studies support the overall complexity of IRF5 alternative splicing in SLE and resulted in the identification and isolation of 14 new differentially spliced IRF5 transcripts. Results from next-generation sequencing correlated with cloning and gave similar abundance rankings in SLE patients, thus supporting the use of this new technology for in-depth single gene transcript profiling. This study provides the first proof that SLE patients express an IRF5 transcript signature that is distinct from healthy donors, and that an IRF5-SLE risk haplotype defines the most abundant IRF5 transcripts expressed in SLE patients. We posit this newly defined workflow of next-generation sequencing for the rapid enrichment, identification, and quantification of differentially spliced transcripts in donor RNA samples. The cytokine macrophage migration inhibitory factor (MIF) counterregulates the immunosuppressive action of glucocorticoids and inhibits activation-induced apoptosis. MIF is encoded in a polymorphic locus with a variant allele frequency >5% and high-expression alleles are associated with clinical severity of rheumatoid arthritis, scleroderma, and asthma but improved outcome from pneumonia. We completed a candidate gene association study in SLE (3195 patients and controls) to examine the relationship between two promoter polymorphisms in MIF: a -794 CATT 5-8 microsatellite repeat (rs5844572), where increased repeat number leads to greater MIF expression; and a -173 G/C SNP (rs755622) that is in linkage disequilibrium with CATT 7 . Patients with the highexpression CATT 7 allele had lower SLE incidence: OR = 0.63, P = 0.001 in Caucasians and OR = 0.46, P = 0.012 in African-Americans. Among patients with established SLE, those with serositis, nephritis, and cerebritis had reduced frequencies of low-expression MIF genotypes (CATT 5 ) when compared with patients without end-organ involvement (P = 0.005 for serositis, P = 0.023 for nephritis, and P = 0.04 for cerebritis). Plasma MIF levels and TLR4, TLR7, and TLR9 stimulated MIF production reflected the underlying MIF genotype of the studied groups. These data suggest that MIF exerts a dual influence on the immunopathogenesis of SLE. High-expression MIF genotypes are associated with a reduced susceptibility to SLE, perhaps by contributing to enhanced clearance of infectious agents. Once SLE develops, however, low-expression MIF genotypes may protect from ensuing inflammatory end-organ damage [1] . We also examined the therapeutic impact of MIF antagonism in two mouse models of spontaneous SLE. In both the NZB/NZW F1 and the MRL/lpr mouse strains, anti-MIF or small molecule MIF receptor antagonism reduced functional and histological indices of glomerulonephritis, MIF-R + leukocyte recruitment, and proinflammatory cytokine and chemokine [2] . A humanized anti-MIF developed from our studies has recently entered phase I clinical testing [3] . These data highlight the importance of MIF in the development of autoimmunity and support the potential clinical feasibility of pharmacologic MIF antagonism. We anticipate that MIF antagonists may be most effectively applied in those individuals who, on the basis of their genotype, manifest a MIF-dependent form of autoimmunity. Patients with systemic lupus erythematosus (SLE) have up to a 50-fold increased risk of developing atherosclerotic cardiovascular disease that cannot be explained by the Framingham risk equation. While both SLEspecific and nonspecific mechanisms have been proposed to play a prominent role in the induction of premature vascular damage in this disease, the exact etiology remains unclear. We have proposed that an imbalance between vascular damage and repair probably induced by IFNα and other type I interferons could play a prominent role in the induction of accelerated atherosclerosis in SLE. Our group and others have recently elucidated the potential role that these cytokines play in the development and progression of premature atherosclerotic disease in SLE and, potentially, in other autoimmune diseases. More recently, a novel role for aberrant neutrophils in the development of autoimmune responses and vascular damage in SLE and other diseases has emerged; in particular, the role that neutrophil extracellular traps may play in the development of this disease and its vascular complications such as endothelial dysfunction and atherothrombosis. The recent description of a distinct subset of proinflammatory neutrophils isolated from lupus patients that induces vascular damage and synthesizes type I interferons has shed new light into a potentially important cell subset implicated in endothelial damage. Finally, novel discoveries pertaining to the interactions of lipoproteins and the immune system may prove quite informative in understanding how premature atherosclerotic plaque develops in lupus. Systemic lupus erythematosus (SLE) is characterized by the dysfunction of T cells, B cells, and dendritic cells, the release of proinflammatory nuclear materials from necrotic cells and the formation of antinuclear antibodies (ANA) and immune complexes of ANA with DNA, RNA, and nuclear proteins [1] . Oxidative stress and inflammation lead to parenchymal and vascular tissue damage, the latter resulting in accelerated atherosclerosis that is a major cause of mortality in SLE. Activation of the mammalian target of rapamycin (mTOR) has recently emerged as a key factor in abnormal activation of T cells and B cells in SLE [2] . In T cells, increased production of nitric oxide and mitochondrial hyperpolarization (MHP) were identified as metabolic checkpoints upstream of mTOR activation. mTOR controls the expression T-cell receptor-associated signaling proteins CD4 and CD3ζ through increased expression of the endosome recycling regulator Rab5 and HRES-1/Rab4 genes [3] , enhances Ca 2+ fluxing and skews the expression of tyrosine kinases both in T cells and B cells, and blocks the expression of Foxp3 and the generation of regulatory T cells [4] . MHP, increased activity of mTOR, Rab GTPases, and Syk kinases, and enhanced Ca 2+ flux have emerged as common T-cell and B-cell biomarkers and targets for treatment in SLE [5] . While inactivation and depletion of B cells have shown success in both animal models and patients, blockade of oxidative stress [6] , mTOR [7] , tyrosine kinases and T-cell-B-cell interaction are also being evaluated as targets for treatment in SLE. Systemic lupus erythematosus is a systemic inflammatory disease characterized by anti-DNA production in association with immune complex deposition. These complexes can deposit in the tissue to incite inflammation as well as stimulate cytokine production by plasmacytoid dendritic cells. While the properties of anti-DNA antibodies have been extensively characterized, little is known about the nature of the DNA in the immune complexes although its origin is generally considered to be cell death. Among sources of extracellular DNA, microparticles (MPs) are small membrane-bound vesicles released from activated and dying cells by a blebbing process. As shown by flow cytometry, these particles display DNA as well as other nuclear molecules in an antigenically accessible form as indicated by the binding of monoclonal anti-DNA antibodies as well as plasma from patients with lupus. Furthermore, plasma from patients with lupus contains increased number of particles with bound IgG, suggesting that MPs can form immune complexes found in lupus. To assess whether MPs play a similar role in murine lupus, we used flow cytometry to measure the presence of MPs with bound IgG in the blood of MRL-lpr/lpr and NZB/W mice; in addition, we tested the binding of plasma of these mice to MPs from apoptotic cells. The results of these studies showed important differences in the serological findings of the two strains as reflected by the much higher numbers of MPs with bound IgG in the blood of MRL-lpr/lpr compared with NZB/W mice. These studies also showed that antibodies from MRL-lpr/lpr mice bound much better to MPs from apoptotic cells than those from NZB/W mice. Since particles in NZB/W blood bound to monoclonal anti-nuclear antibodies as well as MRL-lpr/lpr plasma, these findings indicate antigenic activity despite the lack of particle IgG complexes in NZB/W blood. Together, these studies indicate important differences in the serological features of the two strains as reflected by the capacity of We continue our efforts to define the pathogenesis of systemic lupus-like autoimmunity in predisposed mouse models by focusing on the role of endosomal nucleic acid-sensing TLRs. We reported that NZB mice deficient for the common receptor for type I IFNs showed significant reductions in all disease parameters. To differentiate whether the pathogenic effects were mediated by the multiple IFNα subtypes and/or the single IFNβ, we created congenic NZB mice lacking Ifnb and found that disease severity was unaltered, strongly implicating IFNα subtypes as the principal effectors. We then documented that long-term treatment of male BXSB mice with an anti-IFNAR antibody of mouse origin reduced serologic, cellular and histologic disease manifestations and extended survival, suggesting that disease acceleration by the Tlr7 gene duplication in this model is mediated by type I IFN signaling. The efficacy of this treatment was greater when applied relatively early in the disease process, but reductions in some disease characteristics, especially kidney pathology, were evident even when treatment was initiated at later stages, and a transient therapeutic effect was also noted in the MRL-Fas lpr model. The combined findings suggest that antibody-mediated IFNAR blockade may be a useful treatment approach in human SLE and probably other autoimmune syndromes in which these cytokines appear to play a pathogenic role. We have also hypothesized that engagement of nucleic acid-sensing TLRs may be responsible for spreading the aberrant response beyond ANAs to encompass the broader spectrum of disease-associated autoantibody specificities. Using MRL-Fas lpr mice congenic for the 3d mutation of the Unc93b1 gene, in which signaling by all endosomal TLRs (TLR3, TLR7, TLR9) is extinguished, we indeed found reductions not only in autoantibodies against nucleic acids and associated proteins (anti-chromatin, anti-RNP, anti-Sm), but also in a broad panel of autoantibody specificities, particularly against antigens known to contain or bind to nucleic acids, such as cardiolipin, β 2 -glycoprotein 1 and myeloperoxidase. Surprisingly, even anti-erythrocyte autoantibodies and hemolytic anemia were significantly reduced in NZB mice congenic for the 3d mutation compared with wild-type controls. Thus, almost the entire gamut of autoantibodies in lupus can be traced to the initial engagement of nucleic acid-sensing TLRs. To examine whether engagement of B-cell intrinsic nucleic acid-sensing TLRs is required for autoantibody production in vivo, we generated mixed bone marrow chimeras of B6-Fas lpr mice that were either 3d/IgH b or WT/ IgH a and measured allotype-specific IgM RF and IgG 2a anti-chromatin responses. Strikingly, both autoantibodies were derived almost exclusively from the wild-type donor B cells. This finding underscores the essential significance of B-cell nucleic acid sensors in loss of tolerance and production of autoantibodies in lupus and provides a specific target for intervention. Evidence suggests that plasmacyotoid dendritic cells (pDC), the major producers of type I IFNs, are likely to be involved in the pathogenesis of lupus. One ENU phenovariant identified by Beutler and colleagues, named feeble, showed abrogation of both TLR7-induces and TLR9-induced type I IFN and proinflammatory cytokine production by pDCs, while leaving intact pDC development and TLR responses by other cells. The feeble phenotype was mapped to a mutation in Slc15a4, which encodes the peptide/histidine transporter 1 (PHT1), one of the four members of the solute carrier 15 (Slc15) family of proteins. In preliminary collaborative studies with Beutler and colleagues, lupus-prone B6Fas lpr mice congenic for the feeble mutation showed significant reduction in hypergammaglobulinemia, lymphadenopathy and mortality. These findings provide direct evidence for the role of pDC in the pathogenesis of systemic autoimmunity and suggests that pharmacologic agents that interfere with Sle15a4 function may be useful in treating lupus and other diseases in which these cells appear to be involved. Background: B-cell targeted therapies are important strategies in human systemic lupus erythematosus (SLE). Previous studies have shown that Bcell complement receptor type 2 (CR2/CD21), along with its C3 activation fragment antigen-bound ligand designated C3d, play essential roles in the innate-adaptive immune interface and development of antibodies to foreign antigens. CR2 acts with CD19 to greatly amplify B-cell receptor signals. We hypothesize that a similar role is played by this receptor-ligand pair in the development of high-affinity IgG autoantibodies in patients with SLE. Prior gene-targeting studies have suggested, however, that CR2 expression may be needed to maintain tolerance. These studies are confounded, however, because not only is CR2 absent but due to murinespecific gene structures another receptor designated CR1 is also deleted at the same time. CR1 is a receptor for complement fragment C4b, whose deficiency in humans and murine models leads to lupus. In addition, a recent report of the first identified human CR2-deficient individual revealed a humoral immunodeficiency and not an autoimmune phenotype. Other recent studies have shown in MRL/lpr and (NZB×NZW)F1 mice that the use of soluble CR2 as a potential dominant negative inhibitor led to a substantial decrease in autoantibody titers. Methods: To address our hypothesis, we developed novel mAbs that disrupt the CR2-C3d interface alone, without affecting the interactions of CR1 with C4b. We immunized C3 -/-mice with recombinant human C3d, and Cr2 -/-mice with recombinant murine CR2. Results: The resultant human C3d-reactive mAbs inhibited C3d-CR2 binding, did not recognize intact C3/C3b, and cross-reacted with mouse C3d. Two anti-C3d mAbs, 3d29 and 3d8b, along with control mAb were pre-injected into mice before sheep red blood cell (SRBC) immunization. IgG1 responses to SRBC antigen were substantially decreased, consistent with the interruption in vivo of C3d binding to CR2. One resulting anti-CR2 mAb (4B2, IgG 1 ), which directly blocks binding of C3d to CR2, was injected in wild-type mice and demonstrated no B-cell depletion but maintenance of blockade of CR2 on the B-cell surface for at least 1 month. SRBC immunization of mice pre-injected with mAb 4B2 revealed reduced anti-SRBC levels to levels found in immunized Cr2 -/-mice. No anti-idiotype antibodies were detected. Conclusion: We have developed unique tools to characterize in mouse models of human lupus the pathogenic roles of both the C3d ligand and CR2 components of the CR2-C3d interaction pair. Pregnancy complications in women with the antiphospholipid syndrome (APS) and/or SLE include recurrent miscarriage, preeclampsia, placental insufficiency, and intrauterine growth restriction (IUGR). The mechanisms leading to placental and fetal injury in vivo are incompletely understood and treatment remains sub-optimal. We have identified complement as an early effector in pregnancy loss and/or IUGR associated with placental inflammation in a mouse model of APS and shown that complement activation drives angiogenic imbalance, placental insufficiency and endothelial injury [1] [2] [3] (Figure 1) . The PROMISSE Study (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) is a first-time effort to translate Arthritis Research & Therapy 2012, Volume 14 Suppl 3 http://arthritis-research.com/supplements/14/S3 our novel findings in mice to humans and determine examine the role of complement as a mediator of complications in patients with antiphospholipid (aPL) antibodies and/or SLE. The following discoveries from PROMISSE will be summarized: lupus anticoagulant is the most powerful predictor of poor pregnancy outcomes in aPL-positive patients [4] ; activation of complement early in pregnancy can be detected in the blood of women destined to have preeclampsia; circulating antiangiogenic factors are biomarkers that predict preeclampsia in patients with SLE and/or aPL antibodies and can be released by products of complement activation; and mutations in complement pathway genes that lead to uncontrolled complement activation are associated with preeclampsia in pregnant patients with SLE and/or aPL antibodies [5] . These findings bring us to closer to identifying those at highest risk for pregnancy complications and intervening to block pathways of injury, such as complement. Recent demonstration of the contribution of more than 30 different SNPs to lupus susceptibility has informed our understanding of pathogenesis of disease. Yet each of these genetic variants is commonly found in the general population and contributes a small effect to lupus susceptibility. In contrast, the almost universal association between C1q deficiency and SLE, as well as high relative risk of other classical components, provides a special opportunity to understand mechanisms of disease. The complement pathway was implicated in the immunopathogenesis of lupus and other autoimmune disorders decades ago. The apparent paradox that early complement component (C1q, C2 and C4) deficiencies predispose to lupus has been explained by the beneficial roles of these proteins in promoting the clearance of apoptotic cells and immune complexes (ICs). We recently showed that, in the absence of C1q, instead of ICs binding to monocytes, they preferentially engage plasmacytoid dendritic cells (pDC) so providing a powerful stimulus for the production of IFNα, the cytokine with potent immune adjuvant properties [1, 2] . We confirmed and extended these findings using microarray analysis of total peripheral blood mononuclear cells and purified monocytes following incubation with SLE ICs in the presence or absence of C1q [3] . We observed that C1q suppressed SLE ICinduced interferon-stimulated genes such as TNFSF13B (BAFF) and TNFSF10 (TRAIL), which are associated with SLE pathogenesis. Interferon-independent pathways that were differentially affected by the presence or absence of C1q in SLE ICs included: multiple cytokines/chemokines (for example, CCL20, CCL23), receptors (for example, CD36, STAB1), and enzymes (for example, RNASE1,2,6, SOD2). Exposure of monocytes to SLE ICs was surprisingly noninflammatory even when gene expression was examined by microarray. How then are the lower frequencies of lupus in C4, C2 and C3 deficient patients explained? First, isolated C1q has been shown to exert immunosuppressive properties that have not been identified with C4 or C2. Also, we and others have suggested that C3b may be the key complement protein required for removal of apoptotic cells but that C4b could potentially function in this regard. The lower prevalence of SLE in individuals with a deficiency of C4, C2 or C3 could then be due to only one pathway being defective and, possibly, a functional role for C4b in protection. Future studies will continue to address these questions and guide interventions to promote the safe handling of apoptotic debris and ICs. Only 2% of fetuses exposed to anti-SSA/Ro antibodies have cardiac manifestations of neonatal lupus (cardiac NL, referred to herein as congenital heart block), yet these antibodies are present in >85% of mothers whose fetuses are identified with conduction abnormalities in a structurally normal heart. This disparity implies that the antibodies are necessary but insufficient to cause disease, and that the final pathway to fibrosis may be variable: kept totally in check in most fetuses (normal sinus rhythm), subclinical in others (first-degree block) and fully executed in very few (advanced block). A further challenge to defining the pathology of disease is the intracellular location of the target antigens, thus raising questions regarding accessibility to maternal antibodies. Our research has incorporated three components in the presumed cascade from antibody to tissue injury: apoptosis to provide the antigenic complex; macrophage uptake and secretion to drive inflammation and scarring; and persistence of the myofibroblast to drive replacement of healthy cardiac tissue. The totality of experimental data in the last 2 years supports that the watershed may involve conformational properties of Ro60 that influence its surface translocation to an apoptotic cardiocyte surface, its capacity to bind Y RNA and its effect on the biology of the urokinase plasminogen activator (uPA)/ urokinase plasminogen activator receptor (uPAR) system. By exploiting murine fibroblast cell lines transfected with Ro60 modified to alter RNA binding sites, very recent data suggest that ssRNA (probably hY3 RNA) is required for surface translocation during apoptosis. However, the accessibility of Ro60 to cognate maternal antibody may be influenced by additional factors. In this regard, Ro60 expressed on the surface of an apoptotic cardiocyte binds domain V of β2GPI with high affinity and effectively blocks binding of anti-Ro60 antibodies. In an important translational step to humans, significantly lower levels of circulating β2GPI are associated with disease as assessed with umbilical cord blood comparing affected and unaffected fetuses. The importance of intact β2GPI as a protective factor became increasingly evident as we continued our search for the molecular explanation of a critical observation that anti-Ro60 antibodies inhibit the uptake of apoptotic cardiocytes by healthy cardiocytes. Although a counter-receptor for Ro60 on the healthy cardiocyte was considered, experiments revealed that anti-Ro60 binding to Ro60 (opsonization, formation of immune complexes) is associated with a conformational change of uPAR resulting in two functional consequences, one of which is a 'don't eat me' signal to healthy cardiocytes. The other is uPA activation leading to proteolytic cleavage of plasminogen and the generation of plasmin. The latter cleaves β2GPI, which renders it incapable of binding to Ro60 thus favoring the continued formation of immune complexes on the apoptotic surface. Moreover, the generation of plasmin also promotes the activation of TGF-β. Accordingly, the uPAR/uPA system plays a profibrotic role in the early and expansive phases of disease and the levels of uPAR, uPA, and plasminogen are increased in affected fetuses compared with healthy siblings. The potential of ssRNA to perpetuate an inflammatory step via a Toll-like receptor (TLR)7 pathway has been experimentally substantiated by the transdifferentiation of human fetal cardiac fibroblasts to a scarring phenotype following exposure to supernatants generated by incubation of macrophages with surrogate immune complexes comprised of Ro60, hY3 and affinity-purified anti-Ro60 antibody. Further evidence for a macrophage contribution to injury was provided by immunohistochemistry, which demonstrated not only a macrophage infiltrate in three hearts from anti-Ro-exposed fetuses dying with cardiac NL, but the formation of multinucleated giant cells. With regard to the fibroblast, we posit that these cells are themselves a major source of TGF-β and that endothelin-1 is one of the components responsible for the profibrosing effects generated by TLR signaling in the macrophages. The potential pathologic role of TLR signaling prompted the initiation of a casecontrol study in which we demonstrated that the use of hydroxychloroqine, which inhibits endosomal acidification, decreases the risk of cardiac NL. A prospective study to prevent recurrent disease has just been initiated. to be downregulated in systemic lupus erythematosus and upregulated in rheumatoid arthritis. This miRNA plays a dominant role in the regulation of the innate immune responses. The overexpression or underexpression of miRNAs can influence specific targets and pathways, leading to autoimmune disease phenotypes, and this is also supported by some in vivo studies.
A36
Microparticles as autoantigens in human and murine lupus
A UT O A N T I B O D I E S A N D T I S S U E
Targeting miRNAs could represent a valid future therapeutic option for autoimmune diseases. This discussion will focus on the current understanding in the function of miR-146a in endotoxin tolerance and crosstolerance, and how it may contribute to modulate the overproduction of known pathogenic cytokines.
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Skin-antigen specific antibodies are detected in UV irradiation and TLR7 agonist induced lupus-like disease in autoimmune prone NOD mice and in pediatric SLE M Ghoreishi Introduction: The role of environmental precipitants in autoimmunity such as systemic lupus erythematosus (SLE) remains unclear. We wished to determine whether UV alone or UV in the presence of TLR7 activation would induce lupus-like disease in an autoimmune mouse model, to explore underlying mechanism(s), and relevance in humans. Methods: Six-week-old female nonobese diabetic (NOD) mice received repeated weekly 5,000 j/m 2 UVB radiation or 25 μg topical imiquimod or both. Control mice were left untreated. For comparison, nonobese diabetic resistant (NOR) mice were treated with combination therapy (imiquimod + UV). Serum was collected for detection of anti-nuclear antibodies (ANA), desmoglein 3 (Dsg3) antibodies and IFNα by ELISA and detection of proinflammatory cytokines by cytokine bead array. Peripheral blood was collected for cell surface or intracellular staining using flow cytometry. PAS staining of kidney identified the presence of glomerulosclerosis. Dsg3 antibodies were also measured in the serum of children with SLE, type 1 diabetes (T1D) and normal controls. Results: Imiquimod treatment enhanced ANA and Dsg3 antibody production in NOD mice. Imiquimod + UV induced glomerulosclerosis. Systemic immune activation was detected following combination therapy but not single therapy as evidenced by IL-6, TNFα, IFNγ, and MCP-1. Serum IFNα was significantly elevated in NOD mice following combination therapy. Combination therapy upregulated TLR7 and IFNα expression in the peripheral blood PDCs of NOD but not NOR mice. Anti-Dsg3 antibodies were detected more frequently in children with SLE (5/19) than in children with T1D (1/9) or controls (0/10).
Conclusion: These studies demonstrate that UV light combined with TLR7 engagement induces SLE-like disease in autoimmune prone animals. The presence of anti-Dsg3 antibodies in pediatric SLE suggests that skinspecific autoimmunity occurs in a subset of patients with SLE. 'Omic'-driven research is exploratory in nature, and seeks to interrogate the entire molecular landscape, with the idea that key pathways or nodes that are aberrant in a disease could be uncovered through a brute-force scan. To date, comprehensive profiling using multiple omics platforms has yielded novel insights on a wide spectrum of diseases, as discussed elsewhere [1] . We recently applied a couple of proteomic and metabolomic approaches to study SLE. In particular, we used planar arrays to uncover novel autoantibodies in SLE, as well as novel serum or urine markers of disease. For the latter, we used planar arrays precoated with antibodies to 274 potential biomarker proteins to interrogate the blood and urine of SLE patients. Thirty of the molecules that were upregulated in SLE sera or urine on these arrays were subsequently validated using independent patient cohorts and orthogonal platforms. In addition to confirming several previously reported increases (including increased serum leptin, osteopontin, OPG, TGF, TNFR-II, and VCAM-1 in SLE), this new study also uncovered several additional proteins to be elevated in SLE. One example of the novel serum markers being pursued is sTREM-1. sTREM-1 is elevated in the serum of patients with lupus nephritis and within their kidneys. We have also verified that Trem-1 becomes upregulated in mice subjected to anti-GBM nephritis. This molecule may not only be a marker of disease, it may also constitute a novel therapeutic target because Trem-1 blockade curtails nephritis in the anti-GBM experimental nephritis model. Ongoing studies will test the therapeutic potential of this target in spontaneous lupus nephritis. Additional markers uncovered using the arrays will also be discussed. Omics-based exploratory scans empower us to discern molecules that are differentially expressed in SLE. The challenge ahead is to carefully validate new candidates in order to identify those with the best biomarker or therapeutic potential in SLE. Results: New-onset CKD occurred in 12/41 patients over a median followup of 4.5 years. The CKD group had more RF events than the non-CKD group: 31 (2.59/patient) versus 17 (0.59/patient), respectively, and spent more time in RF (Table 1) . Only 8% of the CKD group versus 59% of the non-CKD group had no RF. In OSS patients with established CKD, those who progressed had more RF events than nonprogressors: 13 (1.63/ patient) versus 2 (0.29/patient), respectively. In the nonprogressor group 71% had no RF, compared with 37.5% of progressors. Progressors had a significant change in SCr over the study period (P = 0.0078). Differences in number of RF and RF duration were not significant between the two groups but tended to be higher in the progressors (Table 2) . Conclusion: In patients with LN, the frequency and duration of RF are biomarkers of new CKD and progression of existing CKD. As new LN therapeutic regimens are developed, targeting RF prevention should be an important goal. Background: It remains unclear why some patients with SLE develop lupus nephritis (LN) and others do not. A reasonable hypothesis is that the inflammatory/immunomodulatory mechanisms in patients with LN are either qualitatively different than in nonrenal (NR) lupus, or that similar pathways are activated but the magnitude of activation is greater in LN. Studies of individual or small groups of candidate cytokines support this idea. To test this hypothesis we examined baseline serum and peripheral blood mononuclear cell (PBMC) cytokine profiles of SLE patients with active LN or NR (mainly arthritis) lupus before entry into a clinical trial of Laquinimod (Teva Pharmaceuticals) as an adjunct antiinflammatory agent for SLE. We sought to determine whether NR or LN was associated with a distinct pattern or level of cytokine expression. Methods: Serum and PBMC from 49 NR and 16 LN patients were collected. PBMC were cultured in medium with or without lipopolysaccharide (LPS), phytohemagglutinin (PHA), or tetanus toxoid (TT). PBMC proliferation was measured after 48 hours, and 38 cytokines were measured in the PBMCconditioned supernatant by Luminex multiplexing. The same cytokines were measured in the sera. Results: LN patients were younger (37 ± 9 vs. 47 ± 14, P < 0.006), had a higher serum creatinine (91.6 ± 28.6 vs. 69.6 ± 16.5 μmol/l, P < 0.0003), higher BILAG score (13.6 ± 8.2 vs. 7.2 ± 3.2, P < 0.0001), higher baseline corticosteroid dose (18.3 ± 1.3.3 vs. 8 ± 8 mg/day, P < 0.004), and were more likely to enter the study taking a concomitant immunosuppressive agent (MMF; 50 vs. 22%). There were no quantitative differences in NR and LN serum cytokine levels for most analytes that were within the limits of detection. Eotaxin and soluble TNF receptor II were greater in LN sera (P = 0.037 and P = 0.022, respectively). Interestingly, IL-17 was not detectable in any LN sample, but was present in 17% of NR sera. LN and NR PBMC proliferated equally well to LPS and PHA, but in response to TT proliferation of NR PBMC was greater than LN PBMC (P < 0.0001). TT did not induce LN PBMC cytokine production. LPS and PHA induced significant increases in production of 24 of the 38 measured cytokines from PBMC, but there were few differences between LN and NR. LPS-induced IL-7 and IL-12 levels were higher from LN PBMC (P < 0.02), and PHA induced more IL-5 production by NR PBMC (P = 0.008). Conclusion: Unexpectedly, no cytokine signature that distinctly separates LN from NR emerged from this survey. This may be due to the greater baseline level of immunosuppression in LN patients, but even with immunosuppression the LN was very active. It is intriguing to speculate that differences, perhaps genetic, in the kidney's response to inflammation, rather than differences in circulating proinflammatory cytokines, determine susceptibility to LN in SLE patients. Background: Outcome measures used in clinical trials of lupus are complex and difficult to interpret. With a plethora of new treatments in development and no objective gold standard to define efficacy, a better understanding of what the different endpoints signify would be helpful in designing more efficient trials and in informing clinicians in practice who need to interpret the results. Methods: Ninety-one patients from the Oklahoma Lupus Cohort (five males, mean age 41) were identified with two visits at which SLEDAI and BILAG scoring had been performed and active disease (SLEDAI >6) was present at the first visit. Each was evaluated by physician judgment as the same, improved or worse at the second visit based on clinical records. Serum cytokine levels were measured by xmap multiplex beadbased assay. Results: At baseline, the mean (SD) PGA, SLEDAI and BILAG scores were 1.75 (0.37), 10.0 (4.09) and 15.1 (6.54). Sixty-eight patients were ranked as improved, 23 as the same or worse at the follow-up visit. The SLE Responder Index (SRI) and BILAG-based Composite Lupus Assessment (BICLA) were compared. Endpoints using these constructs restrict medication use. SRI and BICLA without medication criteria captured physician-ranked improvement (PRI) with 85.3% versus 76.5% sensitivity and 73.9% versus 78.3% specificity. With medication limits, fewer patients were responders, but specificity increased to 82.6 and 95.6%. Similar trends were observed for modified SRI scores (SRI3 and SRI5). Spearman rank correlations to PRI were: SRI3 = 0.605, SRI4 = 0.563, SRI5 = 0.541, BICLA = 0.492 (all P < 0.000001). All nine patients who improved by BICLA but not SRI failed to achieve four-point improvement in the SLEDAI, which requires complete resolution of one or more disease features. However, seven were rated as significantly improved by PRI. All 15 responders to SRI and not BICLA failed to improve in every organ, but 12 were rated as improving by PRI. Biomarkers could provide an objective standard to compare clinical measures. Exploratory evaluation of serum cytokines might allow some preliminary modeling. In the current study IL-6 was only detectable in a minority of patients (n = 29) but decreased significantly in those patients who improved: PRI P < 0.001, SRI3 and SRI 4 P = 0.003, SRI5 P = 0.001, BICLA P = 0.005. Conclusion: SRI5 and BICLA, with the addition of medication restrictions, may be the most specific measures for improvement despite risking loss of sensitivity, and could provide the most meaningful proof of efficacy in an appropriately powered clinical trial. Shortfalls of SRI and BICLA are usually due to the BICLA requiring only partial improvement but in all organs versus SRI requiring full improvement but not necessarily in all organs. Physician's overall opinion corresponds as well as or better than formalized endpoints to improvements of IL-6 in an exploratory biomarker analysis of a lupus patient subset.
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'MiLES' population-based survey of the incidence and prevalence of systemic lupus erythematosus in Southeastern Michigan EC Somers, W Marder, P Cagnoli, EE Lewis, P DeGuire, C Gordon, CG Helmick, L Wang, JJ Wing, JP Dhar, J Liesen, WJ McCune, MiLES GroupArthritis Research & Therapy1478-6354201214Suppl 3A48http://arthritis-research.com/ content/14/S3/A48 Background: We estimated the incidence and prevalence of systemic lupus erythematosus (SLE) in a sociodemographically diverse southeastern Michigan source population of 2.4 million. Methods: SLE cases fulfilling American College of Rheumatology (ACR)SLE classification criteria (primary case definition) or rheumatologist-judged SLE (secondary definition) and residing in Wayne or Washtenaw Counties during 2002 to 2004 were included. Case finding was performed from six source types, including hospitals and private specialists. Age-standardized rates were computed and capture-recapture performed to estimate under-ascertainment of cases. Results: Overall age-adjusted SLE incidence and prevalence per 100,000 were 5.5 (95% CI = 5.0 to 6.1) and 72.4 (95% CI = 70.4 to 74.4); capturerecapture adjusted estimates were 5.6 (95% CI = 5.1 to 6.2) and 71.8 (95% CI = 69.8 to 73.8). For all women the incidence was 9.3/100,000; prevalence was 128/100,000. SLE prevalence was 2.4-fold higher in blacks than whites, and 10-fold higher in women than men. Among the incident cases (ACR definition), mean age (± SD) at diagnosis overall was 39.2 ± 16.6 years. Blacks had a higher proportion of renal disease and end-stage Background: Increased oxidative stress is a major contributor to atherosclerosis (ATH). Patients with SLE demonstrate high oxidative stress and increased ATH. Our group and others have reported several biomarkers and demographic variables associated with increased oxidative stress, including proinflammatory HDL (piHDL), elevated leptin, homocysteine, and increased age -each associated with subclinical ATH in SLE. Can these biomarkers of oxidative stress be combined into a risk profile that better predicts progression of atherosclerosis? Methods: Female SLE subjects not taking statins had B-mode and Doppler scanning of carotid arteries at baseline and 18 to 36 months later. Many biomarkers were tested and those separating plaque presence were chosen for additional analysis. Antioxidant function of HDL was measured as the change in fluorescence intensity caused by oxidation of DCFH after test HDL was added to standardized normal LDL. Values >1.0 indicated piHDL. Plasma levels of leptin and sTWEAK were measured by ELISA; homocysteine was determined by HPLC. Results: Follow-up ultrasounds were completed on 210 SLE women. Overall, 21% (38) of SLE patients had new or larger plaques. Factors associated with plaque progression on bivariate analysis included the baseline presence of plaque (P < 0.001), increased age (P < 0.001), piHDL (P = 0.003), high leptin levels (P = 0.004), high sTWEAK levels (P = 0.004), and diabetes (P = 0.003). Although piHDL was the strongest predictor for plaque progression on multivariate analysis (OR = 5.8, 95% CI = 2.1 to 16.7), with a negative predictive value of 89%, the positive predictive value was only 46%. We used a random forests model to determine which variables were most predictive of plaque progression, and the most significant cutpoints to dichotomize each variable. The most significant predictors were age >48, piHDL, high leptin values ≥34 ng/dl, high sTWEAK >373 pg/ml and high homocysteine (≥12). We then created a PREDICTS cardiovascular risk variable, with low oxidative stress risk defined as zero to two predictors, and high stress defined as ≥3 predictors or one predictor plus diabetes. The high PREDICTS variable had a negative predictive value for plaque progression of 88%, but the positive predictive value was 63%. In multivariate analysis controlling for other cardiac risk factors and disease factors, patients with high PREDICTS had a 10.2-fold increased odds for plaque progression (95% CI = 3.9 to 27.0), and 2.1-fold increased odds for the highest quartile of IMT progression/year (95% CI = 1.05 to 4.4). Conclusion: Formation of a cardiovascular risk model that incorporates several biomarkers and age may provide a more complete means to identify SLE patients at risk for progression of atherosclerosis. Acknowledgements: Body of work supported by NIH (MM), LRI (BH), ALR (BH), and ACR (MM). In 2012, recommended therapies for SLE include antimalarials, glucocorticoids, azathioprine, mycophenolate mofetil (or myfortic acid), cyclophosphamide, and other immunosuppressants. Belimumab has been added recently. Most are targeted toward adaptive immune responses. We now suspect that several pathways in innate immunity are also critical to driving SLE, including dendritic cells (major source of IFNα), and monocyte/macrophages that appear central in the damage that occurs to renal tissue in lupus nephritis. Abnormalities in neutrophils may also drive IFNα production and damage to endothelial cells. Therefore, treatments that modify these innate immune cells are of great interest. Antimalarials primarily suppress antigen-presenting cells (APC), including TLR activation; clinically they suppress disease activity and damage, but not strongly. Glucocorticoids suppress DC, monocytes and lymphocytes, with reduction of trafficking of proinflammatory cells to target tissues, but they are quite toxic. Belimumab is directed primarily at prevention of B-cell maturation and has clinical benefits that are not large when added to standard therapies. Among the potential new therapies that influence APC is Laquinimod, a quinoline derivative administered orally, which has recently been shown to reduce the number of new MRI lesions and disability in patients with multiple sclerosis. A recent study in murine EAE shows that Laquinimod suppresses activity of DC, and prevents monocyte/macrophages from accessing the CNS. Introduction: The Hopkins Lupus Cohort is a longitudinal study in which all SLE patients are seen quarterly, by protocol, by one rheumatologist. The specific aims include prevention of organ damage. In this abstract, two projects -noncalcified plaque (NCP) and treatment of antiphospholipid antibodies -will be reviewed. Methods: For the study on NCP, 64-slice (n = 106) or 320-slice (n = 121) coronary multidetector computed tomography (MDCT) was performed in 227 patients with SLE. The MDCT scans were evaluated quantitatively by a radiologist, using dedicated software. The NCP score was a sum of plaque severity multiplied by the plaque composition divided by the number of vessels examined. For the study on treatment of antiphospholipid antibodies, we studied 1,795 SLE patients (56% Caucasian, 37% African American, 93.3% female, mean age 37.0 ± 12.5) with no previous thrombosis prior to entry in the cohort. The primary outcome was first thrombotic event (arterial or venous). Univariate analysis and multivariable modeling were used to examine associations between prednisone, hydroxycholoquine, and NSAID use with the risk of thrombosis.
Results: The multiple regression model for the mean level of NCP is shown in Table 1 . The multiple regression model for prevention of thrombosis is presented in Table 2 . Background: A recent hospital-based study suggested a 10-fold increased risk of pulmonary embolism among individuals with systemic lupus erythematosus (SLE) in the year following hospital admission. It is unknown whether the risk is similar among the nonhospitalized SLE population. We estimated the risk of incident pulmonary embolism (PE) and deep venous thrombosis (DVT) events, as well as the associated time trend, among incident cases of SLE compared with general population controls using physician billing and hospitalization data for the entire province of British Columbia, Canada (~5 million). Methods: Our data included all visits to health professionals and hospital admissions covered under the province's universal healthcare plan from 1 January 1990 until 31 December 2007 for all individuals ≥18 years of age. We conducted a matched cohort study among patients meeting the following criteria: ≥18 years of age, and new diagnosis of SLE based on the following algorithm: one ICD code for SLE on rheumatologist visit billing data or on hospitalization data, or two ICD codes for SLE at least 2 months and no more than 2 years apart on a physician visit by a nonrheumatologist. Controls were selected from the general population, on a 10:1 ratio for each case, matched by birth year, sex and calendar year of exposure. The outcomes, PE and DVT, we identified based on one ICD code for PE in hospitalization data; and one ICD code for DVT in either outpatient or hospitalization data. We estimated relative risks (RRs) of PE and DVT in SLE cases compared with matched general population controls, after adjusting for age, sex, comorbidities, trauma, fracture, surgery, and hospitalizations. Results: Among 5,156 individuals with SLE, 54 developed PE and 92 developed DVT. Compared with age-matched, sex-matched, and entrytime-matched controls (n = 51,560), the RRs were 4.9 (95% CI = 3.4 to 6.8) for PE and 4.5 (95% CI = 3.5 to 5.7) for DVT. These RRs attenuated slightly after adjusting for covariates, but remained significant (Table 1) . When we evaluated the impact of follow-up time, the RRs for PE, DVT and PE or DVT in SLE patients as compared with non-SLE cases were the largest in the first year ( Table 2 ). The estimates decreased over time and were not significant after 5 years of follow-up with the exception of DVT. Conclusion: This is the first population-based study assessing the risk of PE and DVT in patients with SLE. These findings support increased monitoring of venous thromboembolic complications and risk factors in SLE patients, especially during the first year after disease onset. Background: Results of randomized clinical trials depend on the credibility of the methods reporting to support study findings. Methods: We studied 24 trials from those in the Cochrane Database of Systematic Reviews with 'lupus' in the title and were printable. Each paper was scored by one reviewer using methodological criteria for design, allocation [1] , blinding [2] [3] [4] , reporting and imputation [5] . Scores used yes, no, or ? when it was unclear. Yes n (integer %) for all 24 papers are reported for each criterion. Results: Design: Four (17%) papers had a sample size justification; 22 (92%) contained two groups and two (8%) contained three groups. Five (21%) stratified patients; yet two (8%) used stratification in the analysis. Allocation: Six (25%) stated random numbers generated and three (12%) blocked the balance associated with the allocation ratio; yet zero (0%) used blocking in the analysis. Six (25%) used a randomization list concealed from the person deciding patient eligibility, zero (0%) provided an audit trail for randomization, one (4%) stated randomization integrity. Seven (29%) mentioned the randomization constructed with a computer program or random number table. Blinding: Four (17%) stated the person deciding on the patient eligibility was blinded to block structure and eight (33%) claimed the study was double blinded, even though it was not clear who the two were; indeed one was really triple blinded! For three (12%) patient blinded, six (25%) therapy, four (17%) therapist, one (4%) other caregivers; two (8%) the outcome assessor; zero (0%) data analyst, zero (0%) manuscript writer. Reporting/analysis: One (4%) checked statistical assumptions, 23 (96%) provided baseline data, not all for every patient randomized. Twenty-one (88%) provided P values for group comparisons, four (17%) provided confidence intervals and zero (0%) provided numbers needed to treat. One (4%) specified subgroups in advance [6] , six (25%) adjusted for baseline differences as one of the reported analyses. Four (17%) stated statistical software, but not version, zero (0%) provided the computer used for analyses. Imputation: Seventeen (71%) had missing data, yet one (4%) mentioned using last observation carried forward, zero (0%) used multiple imputation and zero (0%) mentioned impact on study conclusions [5] . Two (8%) provided a flowchart as suggested by CONSORT [7, 8] . Conclusion: Lupus trials did not report many of the methodological criteria that give papers credibility and validity to the study being reported. Reporting should be improved in future reports of studies of patients with lupus and related health problems. Possibly using the CONSORT checksheets would help make lupus papers more credible [7, 8] .
vaccine (PPV) to protect against infection. Response to vaccination may vary due to disease-specific factors and immunosuppressant use. The appropriate time to assess antibody response to PPV is unknown. Our study objectives were to describe the clinical and immunological response to PPV in pediatric SLE and to determine predictors of decline in immunogenicity after PPV. Methods: We evaluated 54 pediatric SLE subjects who received the PPV at diagnosis with vaccine titers obtained at varying intervals. Change in disease activity after vaccination was assessed by the SLE Disease Activity Index (SLEDAI). A positive antibody response was defined as ≥7 of the 14 titers measured having a value ≥1 μg/ml. We used Cox proportional hazards to evaluate factors associated with lack of immunological response to PPV. Results: The majority of the cohort were female (79%) and 52% were Hispanic ethnicity. Nephritis (74%), cytopenias (57%), and arthritis (50%) were the most common clinical features at baseline presentation. In the month prior to vaccination, 54% of the cohort received pulse methylprednisolone, and 20% received cyclophosphamide or mycophenolate mofetil. There was no change in the median SLEDAI score after vaccination (8 vs. 6, P = 0.2). One subject experienced an adverse reaction after initial vaccination, and two subjects developed severe pneumococcal disease despite vaccination. After initial vaccination, 59% of subjects did not achieve protective titers. The median time to inadequate response after initial vaccine was 0.73 years (0.16 to 3.1). In unadjusted models, age (HR = 1.2, P = 0.02, 95% CI = 1.02 to 1.4) and hydroxychloroquine use (HR = 2.4, P = 0.05, 95% CI = 1.0 to 5.7) were associated with a decreased response. However, after adjustment for age, sex, and ethnicity, disease characteristics and medication use were not associated with lack of immunologic response to PPV. Conclusion: PPV was well tolerated in our cohort, but the majority of subjects failed to demonstrate adequate immunologic response to initial vaccination. Disease characteristics and medication use did not explain the lack of response. Pneumococcal infection may occur despite vaccination. PPV vaccination is recommended for patients with pediatric SLE but future studies in larger cohorts are needed to delineate risk factors for lack of immunogenicity.
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Role of anti-Ro autoantibodies in systemic lupus erythematosus patients with recurrent myositis S Umer * , S Hayat, G Caldito, SM Berney Louisiana State University Health Sciences Center, Shreveport, LA, USA Arthritis Research & Therapy 2012, 14(Suppl 3):A57 Background: Anti-SSA (Ro) autoantibodies have been detected in primary Sjögren's syndrome as well as in patients with other systemic autoimmune diseases including systemic lupus erythematosus (SLE). Recent studies have suggested a possible association of anti-Ro antibodies in patients with systemic sclerosis and myositis [1] . These autoantibodies have also been detected in patients with the anti-synthetase antibody syndrome [2] . We investigated the association of anti-Ro antibodies in SLE patients with myositis. Methods: In this retrospective study, we reviewed the records of 160 patients with SLE followed in the lupus clinic at LSU Health Sciences Center, Shreveport from 2000 to August 2012. Results: We identified 16 patients (10%) with myositis and SLE. Patients with possible secondary cause of myositis, such as thyroid disease and drug, were excluded. All of the patients were females. Fourteen patients (87.5%) were African Americans and two (12.5%) were Caucasians with ages that ranged from 15 to 69 years. Among these 16 patients, 12 (75%) were found to have anti-Ro autoantibodies. The remaining four patients were not tested for anti-Ro. Five patients (41.7%) with higher levels of antiRo antibodies at the beginning of their disease experienced recurrences of the myositis. Average anti-Ro was compared between patients with and without recurrences to determine association between myositis recurrence and anti-Ro. A nonparametric test (Wilcoxon rank sum test) was used to do the comparison due the observed non-normal distribution of anti-Ro and the small sample sizes (five and seven) for the two groups compared. Mean ± SD for the recurrence and nonrecurrence groups was 470.4 ± 347.3 and 153.5 ± 113.4, respectively. Using the Wilcoxon rank sum test, the P value for the comparison was 0.06. This was not significant at the 5% level but significant at the 7% level (P < 0.07). The observed nonsignificance at the 5% level was due to the small sizes (five and seven) for the two groups compared Conclusion: The observed results show possible association between myositis recurrence and anti-Ro antibody level. Prospective studies are required to further investigate this association. Myositis in SLE may be under-reported secondary to a lack of awareness of this association, which precludes the simultaneous testing of these autoantibodies along with muscle enzymes. This evaluation is vital during the beginning of disease and with flares because the ongoing muscle damage may be masked and undertreated by the subsequent therapy. 
